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ABSTRACT 
 Black women have higher incidence rates of aggressive subtypes of 
endometrial cancer and worse survival rates compared with white women. The 
overall incidence rate has been increasing in black women and, accounting for 
their higher prevalence of hysterectomy, may be higher than in white women. 
Exposures related to obesity and metabolic disorders, reproductive factors, and 
use of exogenous hormones have been associated with endometrial cancer risk 
in prior studies. However, because these studies have primarily included white 
women, little is known about these associations in black women. We therefore 
examined associations of endometrial cancer with previously identified risk 
factors in 47,555 participants in the Black Women’s Health Study, a prospective 
cohort of U.S. black women. 
 Study 1 focused on anthropometric and metabolic factors. After 
adjustment for age at menarche, parity, menopausal status, smoking, and use of 
oral contraceptives, estrogen-only female menopausal hormones (FMH), and 
estrogen plus progestin FMH, self-reported body mass index (BMI), BMI at age 
18, greater weight gain since age 18, and diagnosis of diabetes were positively 
 viii 
 
associated with endometrial cancer risk. Self-reported diagnosis of 
hypercholesterolemia and hypertension were not independently associated.  
 In study 2, we examined associations with reproductive factors. 
Endometrial cancer incidence was higher among women with early age at 
menarche, a history of infertility, a greater number of lifetime menstrual cycles, 
and diagnosis of polycystic ovary syndrome. Parity and early age at first birth 
were associated with lower risk, while a greater number of births and 
breastfeeding were not associated with risk. Positive associations with late age at 
menarche among premenopausal women and longer duration of breastfeeding 
among obese women require confirmation in other studies. 
 In study 3, we examined the associations of endometrial cancer with 
exogenous hormone use. The inverse association with oral contraceptive use 
was primarily among women who used oral contraceptives for ≥5 years. 
Incidence was higher among current users of estrogen-only and estrogen plus 
progestin FMH, and ever users of progestin only FMH. Lower risk was observed 
among former users of estrogen plus progestin FMH. 
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1 Introduction 
 Endometrial cancer is the most common gynecologic cancer, and ranks as 
the 4th most common cancer in the U.S.41 and the 5th most common worldwide17 
among women. While incidence rates are lower than they were 40 years ago,41 
recent evidence suggests they are increasing.50 The five-year survival rate is 
around 80% for all types combined,41 but is as low as 20% for some rare, 
aggressive histologic subtypes.2 Overall five year survival rates have decreased 
over the last 40 years.41 
 The principle mechanism of pathogenesis for endometrial cancer is 
summarized in the unopposed estrogen hypothesis.23 Estrogens are agonists for 
proliferation of endometrial tissue, while this action is blocked in the presence of 
progestogens. Endometrial cancer risk is dependent on the mitotic rate of the 
endometrium.23 This is presumably due to the accumulation of mutations caused 
by errors in DNA replication during mitosis, although other mechanisms are 
possible. Thus, according to this hypothesis, exposures that increase the level of 
estrogen and/or decrease progestogens in the endometrium will increase risk, 
while decreases in estrogen and/or increases in progestogens will be protective. 
Factors associated with increased risk include obesity,7,10,11,16,18,30,36,38,42,44,46,49,52 
early age at menarche, late age at menopause, an increased number of 
menstrual cycles,14,21,24,31,38,51,52 and use of estrogen-only female menopausal 
hormones (FMH).3,6,15,25,35,45 Parity,9,14,21,31,33,51 breastfeeding,9,37,51 and the use 
of oral contraceptives1,4,13,14,19,22,26,29,43,47,48 are associated with decreased risk. 
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The majority of the research on risk factors for endometrial cancer has 
been conducted in white women. This is exemplified by a recent meta-analysis of 
the association of endometrial cancer with oral contraceptive use which 
combined 36 studies and included 27,276 cases.12 Of these, 351 cases were 
non-white, leading the authors to conclude that they had insufficient power to 
examine differences by race.12 Yet the risk of endometrial cancer differs among 
black and white women. A recent study found that, while incidence has long been 
thought higher among white, compared with black, women, it is actually higher 
among black women after accounting for their higher prevalence of 
hysterectomy.20 The rates of more aggressive subtypes are also higher for black 
women.20,40 Black women have higher mortality than white women, even 
accounting for differences in tumor characteristics.5,32,34 The reasons for these 
differences are not well understood. Among the possible explanations is that the 
associations of endometrial cancer with previously identified risk factors differ in 
black and white women. A recent pooled analysis including 516 black and 5,693 
white cases explored this question, and failed to find substantial differences.13 
Black women also differ in the prevalence of risk factors such as obesity,8 
patterns of childbirth,27,28 and use of female menopausal hormones39 which may 
account for some of the difference in risk among black and white women. 
The primary goal of this dissertation is to contribute to the understanding 
of the etiology of endometrial cancer among black women by investigating its 
associations with risk factors identified in previous research. In Study 1, we 
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examined the association of endometrial cancer with measures of overall and 
central obesity, along with components of metabolic syndrome. Study 2 focused 
on associations with reproductive factors. In study 3, we investigated the 
associations of exogenous hormone use with endometrial cancer. All three 
studies utilized data from the Black Women’s Health Study, a large prospective 
cohort of U.S. black women. Due to the collection of additional data over the 
course of the research, studies 2 and 3 differ from study 1 in number of cases 
(300 and 274, respectively) and total number of participants included (47,555 and 
47,557, respectively). 
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2 Body Size, Metabolic Factors, and Risk of Endometrial Cancer in 
Black Women 
 
2.1  Abstract 
Background: Total and abdominal obesity, as well as metabolic factors such 
as type 2 diabetes, have been associated with a higher risk of endometrial 
cancer in white women. It remains unclear to what extent these factors 
influence the risk of endometrial cancer in black women.  
 
M e t h o d s :  We followed 47,557 participants from the Black Women’s Health 
Study for incident endometrial cancer from 1995 through 2013 (n = 274). We 
used Cox regression models to estimate incidence rate ratios and 95% 
confidence intervals while accounting for potential confounders.  
 
Results: Incidence rate ratios for body mass indices (weight (kg)/height 
(m)2) of 25.0–29.9, 30.0–34.9, 35.0–39.9, and ≥40.0 versus those <25.0 
were 1.00 (95% confidence interval (CI): 0.67, 1.48), 1.49 (95% CI: 0.97, 
2.30), 2.16 (95% CI: 1.34, 3.49), and 3.60 (95% CI: 2.24, 5.78), respectively 
(Ptrend  <0.0001).  A high weight-to-height ratio was also associated with a 
higher risk (for the highest quartile vs. the lowest, incidence rate ratio=2.83, 
95% CI: 1.77, 4.53), as was type 2 diabetes mellitus (incidence rate 
ratio=1.52, 95% CI: 1.04, 2.21). Positive associations with measures of 
 10 
 
central adiposity (waist circumference, waist-to-hip ratio, and waist-to-height 
ratio) and hypertension were attenuated after we controlled for body mass 
index.  
 
Conclusions: Total adiposity was an independent risk factor for 
endometrial cancer among black women and appeared to explain most of 
the associations seen with other adiposity measures and metabolic factors. 
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2.2 Introduction 
In studies including primarily white women, there has consistently been a 
strong relationship between body mass index (BMI), a measure of total adiposity, 
and endometrial cancer risk.5,10,12,20,28,38,43,45,51–53,55,59 Likewise, endometrial 
cancer has been associated with measures of central adiposity, such as waist 
circumference 2,10,17,18,23,43 and waist-to-height ratio,10,18 as well as measures of 
peripheral body fat, such as hip circumference,2,18,23 and body fat distribution, 
such as waist-to-hip ratio.2,10,18,23 In the sole study in which investigators adjusted 
for BMI when estimating associations of other adiposity measures with 
endometrial cancer,23 the associations were attenuated. 
In numerous studies, researchers have found an association between 
diabetes and endometrial cancer.13,14,17,20,21,24,33,36,37,42,43,59 Two recent meta-
analyses showed a higher risk in diabetic women, but results among studies were 
heterogeneous.21,36 The evidence supporting associations with other metabolic 
factors, such as high triglyceride levels,17,24,46 low levels of high-density 
lipoprotein,17,24,46 and hypertension,17,24,43 is less clear. 
Adipose tissue may affect endometrial cancer risk through its expression of 
aromatase, which converts androgens to estrogens.50 Mitotic activity in 
endometrial cells is primarily regulated by sex steroid hormones, with 
proliferation stimulated by estrogen and inhibited by progesterone.29 According to 
the unopposed estrogen hypothesis,31 any factor that increases estrogen levels or 
decreases progesterone levels would increase cancer risk. Metabolic factors, 
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particularly diabetes, have been associated with lower levels of sex hormone–
binding globulin and therefore higher levels of bioavailable estrogen.54 
We prospectively evaluated the association of endometrial cancer with 
measures of overall obesity (BMI, weight-to- height ratio), central adiposity 
(waist circumference, waist- to-hip ratio, waist-to-height ratio), and peripheral 
adiposity (hip circumference), as well as 3 metabolic factors (type 2 diabetes, 
hypercholesterolemia, and hypertension) in a large cohort study of black women 
in the United States. 
 
2.3 Methods  
2.3.1 Data Source 
In the present investigation, we used data from the Black Women’s Health 
Study (BWHS), an ongoing prospective cohort study initiated in 1995.44 A total 
of 59,001 self-identified black women aged 21–69 years were recruited primarily 
from the subscription list of Essence magazine. At baseline, information about 
demographic factors, reproductive history, health history, anthropometric 
measurements, dietary intake, and use of tobacco, alcohol, vitamins, and select 
medications was collected via self-administered mailed questionnaires. 
Participants complete follow-up questionnaires every 2 years to update outcome, 
exposure, and covariate data; follow-up of the baseline cohort has been complete 
for 88% of potential years of follow-up through 2013. The study was approved by the 
institutional review board of Boston University, Boston, Massachusetts. 
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2.3.2 Exclusions 
In the present analysis, women were excluded if they reported a history of 
uterine cancer (n=264), cervical cancer (n=74), or hysterectomy (n=10,569) at 
baseline; had unknown menopausal status at baseline (n=90); or did not return a 
questionnaire subsequent to the baseline questionnaire (n=447). The analytic 
sample comprised the remaining 47,557 women who were followed for incident 
endometrial cancer from 1995 through 2013. During follow-up, 6,499 women 
were censored after reporting that they had undergone a hysterectomy and 235 after 
reporting that they had undergone a gynecologic surgery of unknown type. 
 
2.3.3 Outcome 
Participants reported new diagnoses of “uterine cancer” on biennial follow-
up questionnaires from 1997 through 2013. The 1995 and 2011 questionnaires 
did not ask specifically about uterine cancer but asked participants to report 
any “other serious illness.” Cases were also identified through state cancer 
registry records. In total, there were 313 potential incident cases. Eighteen of 
these women told us they had a condition other than uterine cancer when 
contacted for permission to release medical records. We obtained medical 
records, cancer registry data, or death certificate data for 216 potential case 
patients. All but 16 were confirmed as having either endometrial cancer (n=195) 
or uterine sarcoma (n=5). Because the confirmation rate was high, we accepted 
the remaining potential cases as cases of incident endometrial cancer. Thus, 
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after the exclusion of uterine sarcomas, there were a total of 274 cases of 
endometrial cancer (195 confirmed and 79 unconfirmed) available for study. 
 
2.3.4 Exposures 
Waist circumference, hip circumference, weight at age 18 years, and height 
were reported on the baseline questionnaire. Waist and hip circumference 
measurements were updated in 2005. Current weight, history of diagnosis of 
“diabetes not during pregnancy,” hypertension, and hypercholesterolemia were 
reported at baseline and on each follow-up questionnaire. All exposures and 
covariates updated by questionnaire after baseline were considered time-varying. 
We examined 2 measures of total adiposity: BMI and weight-to-height ratio. BMI 
was defined as weight in kilograms divided by height in meters squared and 
weight-to-height ratio as weight in kilograms divided by height in meters. The 
correlation between these 2 measures was high (r = 0.98; P < 0.0001). Waist-to-hip 
ratio was calculated as waist circumference in centimeters divided by hip 
circumference in centimeters. Weight change since age 18 years was calculated 
as the difference between reported weight at each questionnaire and reported 
weight at 18 years in kilograms. BMI was categorized as <25.0, 25.0–29.9 
(overweight), 30.0–34.9 (class 1 obesity), 35.0–39.9 (class 2 obesity), or ≥40.0 
(class 3 obesity), and BMI at age 18 was categorized as <18.5, 18.5–24.9, 
25.0–29.9, or ≥30.0.  Weight-to-height ratio at age 18 years, current weight-to-
height ratio, waist-to-height ratio, hip circumference, and height were categorized 
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into quartiles. We categorized waist circumference as <80, 80–87, or ≥88 cm 
based upon action levels recommended by Lean et al.34 A waist-to-hip ratio of 0.85 
or greater58 is commonly used to define abdominal obesity. We therefore 
categorized waist-to-hip ratio as <0.80, 0.80–0.84, and ≥0.85. Change in weight 
since age 18 years was categorized as <−5, −5 to 4, 5 to 14, 15 to 24, 25 to 34, 
35 to 44, or ≥45 kg. Women who reported diabetes diagnosed after 30 years of age 
were considered to have type 2 diabetes. Those who reported hypertension and 
treatment with hypertension medications or diuretics were considered to have 
hypertension. Similarly, hypercholesterolemia was defined as self-report of 
hypercholesterolemia plus self-reported use of cholesterol-lowering medication. 
In a validation study among 115 participants in the Black Women’s Health 
Study who resided in the Washington, DC, area, correlation coefficients between 
self-reported and technician-measured height, weight, waist circumference, and 
hip circumference were 0.93, 0.97, 0.75, and 0.74, respectively.57 In another 
validation study, Krishnan et al.32 found that 96% of the diagnoses of type 2 
diabetes among a subset of 227 self-reported cases were confirmed by physicians. 
Among a subset of 139 women who reported incident hypertension between 
1999 and 2001 and for whom medical records were obtained, diagnosis was 
confirmed in 99%.16 
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2.3.5 Covariates 
At baseline and on biennial questionnaires, participants reported data on 
reproductive history (age at menarche, age at menopause, parity), menopausal 
status, diagnosis of uterine fibroids, oral contraceptive use, postmenopausal 
female hormone use, alcohol consumption, smoking status, state of residence, 
breastfeeding, participation in vigorous exercise (such as basketball, swimming, 
running, or aerobics), medication use, marital status, educational level, household 
income, and parental and partner/spouse educational level. Energy intake was 
calculated from food frequency questionnaires administered in 1995 and 2001.8,9 
 
2.3.6 Data analysis 
Participants contributed person-time from baseline until the reported 
diagnosis of endometrial cancer or 1 of the following censoring events: reported 
diagnosis of a non-endometrial uterine cancer (e.g., leiomyosarcoma), hysterectomy, 
loss to follow-up, death, or the end of follow-up (2013), whichever came first. We 
calculated incidence rates and rate ratios for all categories of exposure compared 
with the reference category using SAS software, version 9.4 (SAS Institute, Inc., 
Cary, North Carolina). We used Cox proportional hazards regression models15 
stratified by age and questionnaire cycle to calculate adjusted incidence rate ratios 
and 95% confidence intervals. The Andersen-Gill data structure3 was used to 
accommodate time-varying covariates. Departures from proportional hazards were 
assessed by comparing models with and without interaction terms between 
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exposures and each of the time scales (age and questionnaire cycle) using the 
likelihood ratio test. 
We controlled for covariates that were established risk factors for 
endometrial cancer or that were associated with body size in our cohort, including 
age at menarche (<11, 11, 12–13, or ≥14 years), parity (0, 1, 2, 3, or ≥4 births), 
menopausal status (premenopausal or postmenopausal), oral contraceptive use 
(never, former, or current), use of both estrogen-only and estrogen plus progestin 
female hormones (never, former, or current), smoking status (never, former, or 
current smoker), amount of vigorous physical activity (0, 1–4, or ≥5 hours/ 
week), type 2 diabetes, hypertension, and hypercholesterolemia. Analyses of 
BMI and weight-to-height ratio were additionally adjusted for waist 
circumference. Analyses of measures of central and peripheral adiposity and 
metabolic factors were additionally adjusted for BMI (<25.0, 25.0–29.9, 30.0–
34.9, 35.0–39.9, or ≥40.0). We additionally adjusted analyses of diabetes, 
hypertension, and hypercholesterolemia for use of metformin and statins (ever vs. 
never). Inclusion of potential confounders including income, educational level, age 
at first birth, age at last birth, ever diagnosis of uterine fibroids, pack-years of 
smoking, alcohol consumption, marital status, geographic region of residence, 
energy expenditure from exercise, and energy intake did not substantially change 
point estimates in our models. These variables were therefore omitted from the 
final models. 
We performed tests for linear trend by modeling the median value for 
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each exposure category as a continuous variable and calculating a Wald test 
statistic association with this variable. The partial population attributable risk 
(PAR) for obesity was calculated using the SAS PAR macro.49 The model used 
was the same one used for the metabolic factors in the main analysis, except that 
we controlled for age (10-year categories) and study period (continuous) to 
explicitly account for their covariance with obesity rather than stratifying on these 
variables.49 
We reanalyzed the data to evaluate whether our results were similar 
when unconfirmed cases were excluded from the outcome. 
 
2.4 Results 
As shown in Table 1, women who were overweight (BMI 25.0–29.9) or 
obese (class 1: BMI 30.0–34.9; class 2: BMI 35–39; class 3: ≥40.0) at baseline 
tended to be older, postmenopausal, and heavier at age 18 years and were more 
likely to have gained more weight since 18 years of age. In addition, they were 
more likely to have larger waist circumferences; were more likely to be 
diagnosed with diabetes, hypertension, or hypercholesterolemia; had an earlier 
age at menarche; exercised less; and smoked more. 
As shown in Table 2, compared with persons with BMIs less than 25, the 
adjusted incidence rate ratios increased with increasing BMI to 3.60 (95% 
confidence interval (CI): 2.24, 5.78) for women with BMIs of 40 or higher. When 
comparing the highest quartile of weight-to-height ratio with the lowest, the 
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multivariable incidence rate ratio was 2.83 (95% CI: 1.77, 4.53). There was little 
evidence of associations between measures of central adiposity (waist 
circumference, hip circumference, waist-to-hip ratio, and waist-to-height ratio) 
or height with incident endometrial cancer after adjustment for potential 
confounders, including BMI. 
Obesity at 18 years of age was also positively associated with 
endometrial cancer (Table 3). The multivariable incidence rate ratio for BMI at 
age 18 years of 30.0 or higher versus 18.5–24.9 was 1.99 (95% CI: 1.26, 3.15). 
A similar increase was seen for the highest versus the lowest quartile of weight-
to-height ratio at age 18 years (incidence rate ratio=1.64, 95% CI: 1.16, 2.32). 
Risk of endometrial cancer increased with increasing weight gain since age 18 
years; the incidence rate ratio was 2.30 when comparing the highest categories of 
weight gain with the lowest (95% CI: 1.03, 5.12). 
The multivariable-adjusted incidence rate ratio for type 2 diabetes was 
1.52 (95% CI: 1.04, 2.21) (Table 4). The incidence rate ratios for hypertension 
and hypercholesterolemia were 1.02 (95% CI: 0.78, 1.33) and 0.92 (95% CI: 0.67, 
1.27), respectively. However, the incidence rate ratio for women with 
hypercholesterolemia who had ever used statin medications (44 of 94 cases) 
relative to women without hypercholesterolemia was 0.67 (95% CI: 0.46, 0.97). 
After accounting for other risk factors for endometrial cancer, the estimated 
PAR for obesity was 30.3%, (95% CI: 10.4, 47.8). Analyses confined to confirmed 
cases yielded associations that were similar to those given above but generally of 
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greater magnitude (Appendix 1, Tables 13, 14, 15). 
 
2.5 Discussion 
In the present large prospective study of U.S. black women, total obesity 
(measured using BMI and weight-to-height ratio) was strongly associated with 
a higher incidence of endometrial cancer. Obesity at 18 years of age and the 
highest category of weight gain since age 18 years were also associated with 
increased risk. Associations with central obesity measures, including waist 
circumference, waist-to-hip ratio, and waist-to-height ratio, were either weak or 
absent after adjustment for BMI. Type 2 diabetes was associated with a higher 
risk of endometrial cancer, whereas no association was observed for either 
hypertension or hypercholesterolemia. An inverse association was observed for 
women with high cholesterol who had ever used statin medications, but there 
were insufficient data to assess timing and duration of use. 
Several mechanisms could explain the association between obesity and 
endometrial cancer. Adipose tissue is known to express aromatase, an enzyme 
that converts androgens to estrogens. Aromatization of androgens in local tissues 
makes a minor contribution in premenopausal women but becomes the primary 
source of estrogen after menopause.48 In addition, greater adiposity is associated 
with disruption of metabolism. The increased levels of insulin and insulin-like 
growth factor 1 seen in diabetics have been associated with growth of endometrial 
cancer cells in vitro, as well as with increased cancer risk in women.41 Increased 
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blood insulin levels are also associated with lower levels of sex hormone 
binding globulin, which binds to circulating estrogen and decreases its 
bioavailability.54 
In previous studies, it has been suggested that visceral adipose tissue 
may be more closely associated with blood lipids and insulin resistance,26,35 but 
express less aromatase4 than subcutaneous adipose tissue. Various adipose 
tissue depots may therefore differ from one another in their association with 
endometrial cancer risk. Numerous proxy measures have been developed that 
differ in ease and reliability of measurement and correlation to the various 
adipose tissue depots.40 BMI and weight-to-height ratio measure total adiposity 
without reference to its distribution in the body. Waist circumference and 
waist-to-height ratio are used as measures of abdominal adiposity and 
abdominal adiposity adjusted for overall body size, respectively.40 Hip 
circumference measures peripheral adiposity, specifically gluteal- femoral 
deposits, which is correlated to estrogen levels in women56 and may be 
metabolically more benign than abdominal fat.7,27 Waist-to-hip ratio adjusts 
abdominal adiposity for peripheral adiposity. 
Similar to prior studies in white women,2,5,10,12,20,23,28,38,43,45,51–53,55,59,60 we 
found a strong positive association between BMI and endometrial cancer risk. In 
addition, investigators in previous studies have reported 2- to 3-fold increases 
in risk associated with higher waist circumference,2,10,17,18,23,43 hip 
circumference,2,18,23 waist-to-hip ratio,2,10,18,23 and waist-to-height ratio .10,18 
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However, in most of these studies, there was no adjustment for BMI;2,10,17,18,43 in 
the 1 study that did include adjustment,23 researchers found that it attenuated 
most associations, similar to our findings. In our study, abdominal obesity was not 
associated with endometrial cancer risk after controlling for overall adiposity. This 
implies that it is the overall amount of adipose tissue, rather than the amount 
located in the abdomen or the gluteal-femoral region, that is important for 
endometrial cancer risk. 
Weight-to-height ratio appeared to be at least as strongly related to 
endometrial cancer risk as BMI in the present study. We have identified only 1 
other study in which the authors explored the relationship between weight-to-
height ratio and endometrial cancer30 and also observed a strong positive 
association. Because the denominator in BMI is squared, whereas that for 
weight-to-height ratio is not, BMI would be expected to retain a greater 
correlation to height than would weight-to-height ratio.1 Weight-to-height ratio 
may therefore be a better measure of total adiposity independent of height. 
It is unclear whether the risk of endometrial cancer among women who are 
obese throughout their adult lives differs from that of women who become obese 
later in life. As in most previous studies, our results suggest that higher BMI in early 
adulthood10,11,18,28,38 and large weight gain2,10,11,28 are associated with higher 
endometrial cancer risk but do not suggest a greater risk for adiposity in early 
adulthood compared with adiposity later in life. As in these prior studies, we had 
insufficient numbers of cases, especially those with high BMIs in early adulthood, 
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to address this issue adequately. 
Among metabolic factors, diabetes and high blood glucose have been most 
consistently associated with endometrial cancer risk in the 
literature.13,14,17,20,22,24,33,36,37,42,43,59 Two recent meta-analyses reported 
summary relative risks of 2.122 and 1.636 for endometrial cancer when 
comparing women with and without diabetes. However, both reported 
substantial heterogeneity in covariates and results among studies and noted 
that estimates from case-control studies tended to be greater than those from 
cohort studies. The estimated association among black women observed in a 
recent pooled analysis is comparable to the association observed in the present 
study.14 The evidence that other metabolic factors (high triglyceride levels,17,24,46 
low levels of high- density lipoprotein,17,24,46 and hypertension17,24,43) are 
associated with endometrial cancer is more equivocal. We found little support for 
associations of hypertension and hypercholesterolemia with increased 
endometrial cancer risk. In 2 prior studies,25,51 investigators observed an inverse 
association between cholesterol and endometrial cancer risk, but others have not 
found associations between high-density lipoprotein or total cholesterol levels 
and endometrial cancer.17,24,43,46 
Obesity was both strongly associated with endometrial cancer risk and 
highly prevalent in our study population. If we assume that the observed 
association is causal, then obesity accounted for more than 30% of the cases. 
Calculating rough estimates based on the associations of obesity with 
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endometrial cancer risk and prevalence of obesity from previously published 
cohort studies produces PARs of 0.10 using data from the European Prospective 
Investigation into Cancer and Nutrition23 and 0.30 using data from the Nurses’ 
Health Study/Nurses’ Health Study II.19 We estimated PARs separately for black 
and white women using data from the Multi-Ethnic Cohort47 and found PARs of 
0.23 for white women and 0.39 for black women. Comparisons among the 
studies are hindered by differences in age and other important factors. 
Strengths of the present study include its prospective design, large study 
size, high rates of participation, and control for a large number of potential 
confounders. We had data available to evaluate a wide variety of adiposity 
measures, both during follow-up and in early adulthood. A validation study found 
the accuracy of reporting of the anthropometric measures to be good to 
excellent.57 The definitions for diagnoses of type 2 diabetes32 and hypertension16 
have previously been validated. 
Our study has several limitations. Errors in self-report of endometrial cancer 
may have altered associations. However, when we confined the analyses to 
confirmed cases only, the associations were similar but generally stronger. 
Although prior validation studies showed that self-reported weight and height were 
in excellent agreement with technician measures, misclassification of waist- and 
hip circumferences (and therefore of their ratio) was greater57 and could have 
contributed to the null results for waist-to-hip ratio. The result of misclassification of 
the exposures would have been to bias towards the null for dichotomous variables; 
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the bias is not predictable for specific categories of non-dichotomous variables, 
although for the extremes it would have been toward the null. Although we have 
data on a large number of potential confounders, we cannot exclude the possibility 
of residual confounding. 
In summary, there was a strong positive association of endometrial cancer 
incidence with both BMI and weight-to-height ratio in this prospective study of U.S. 
black women, consistent with previous studies of white women. Notably, women 
with class 3 obesity (BMI ≥40; 21% of the cases) had a 3-fold higher incidence 
of endometrial cancer compared with women who were not overweight. The 
prevalence of obesity among black women is increasing faster than that in other 
ethnic groups,6 whereas overall hysterectomy rates are decreasing.39 Therefore, 
the risk of endometrial cancer for black women may be expected to increase in 
the future. 
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Table 1. Baseline Characteristics of Study Participants According to Body Mass Index, Black Women's Health Study, 1995 
Characteristica 
BMIb Category kg/m2 
<25 25–29 30–34 35–39 ≥40 
n=18,972 n=13,941 n=7,039 n=3,305 n=2,636 
Age, years, mean (SD) 34.5 (9.1) 38.0 (10.1) 38.5 (10.1) 37.9 (9.8) 37.4 (9.3) 
BMIb, kg/m2, mean (SD) 22.3 (21.5) 27.3 (18.2) 32.3 (20.0) 37.3 (21.5) 45.1 (75.5) 
BMIb at age 18, kg/m2, mean (SD) 19.8 (26.1) 21.4 (37.8) 23.2 (52.7) 25.3 (66.7) 28.7 (101.9) 
Height, cm , mean (SD) 166.1 (83.1) 165.6 (90.3) 165.1 (97.9) 165.4 (109.6) 165.2 (120.2) 
Weight-to-height ratioc, mean (SD) 37.0 (38.2) 45.2 (38.5) 53.2 (45.6) 61.6 (54.4) 75.1 (133.8) 
Waist circumference, cm, mean (SD) 71.5 (89.4) 81.8 (115.4) 89.8 (141.8) 96.0 (175.0) 107.3 (261.6) 
Hip circumference, cm, mean (SD) 93.5 (102.4) 103.3 (126.6) 110.6 (152.8) 118.0 (202.1) 131.8 (286.7) 
Waist-to-hip ratio, mean (SD) 0.8 (1.1) 0.8 (1.3) 0.8 (1.5) 0.8 (1.6) 0.8 (1.9) 
Waist-to-height ratio, mean (SD) 0.43 (0.53) 0.49 (0.67) 0.54 (0.85) 0.58 (1.06) 0.65 (1.53) 
Change in weight, age 18 to baseline, kg, mean (SD) 7.4 (7.1) 16.7 (114.7) 24.7 (150.6) 32.8 (193.4) 45.6 (300.3) 
Type 2 diabetes, % 1.0 3.0 5.4 7.1 8.7 
Hypertension, % 10.5 19.9 27.6 33.5 40.4 
Hypercholesterolemia, % 13.4 19.2 20.9 22.4 21.5 
Vigorous physical activity, hours/week, %      
     1–4 55.8 55.8 53.8 48.4 41.0 
     ≥5 18.1 18.1 13.9 7.4 5.7 
Age at menarche, years, %      
     <12 21.9 21.9 27.5 36.8 43.6 
     12–13 54.7 54.7 53.9 48.2 43.6 
     ≥14 22.9 22.9 18.1 14.6 12.4 
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Table 1. continued 
Parity, %      
     0 46.6 46.6 33.0 36.5 39.3 
     1–2 41.2 41.2 46.9 41.9 39.5 
     ≥3  12.1 12.1 19.9 21.4 21.2 
Postmenopausal, % 6.6 6.6 12.4 11.3 9.9 
Ever used oral contraceptives, % 86.7 86.7 86.3 82.5 78.8 
Ever used estrogen-only FMH, % 1.1 1.1 1.7 1.5 1.6 
Ever used estrogen plus progestin FMH, % 2.9 2.9 4.4 3.1 2.6 
Ever smoked cigarettes, % 27.5 27.5 35.9 36.2 35.9 
Abbreviations: BMI, body mass index; FMH, female menopausal hormones, SD, standard deviation. 
a All characteristics (with the exception of age) are standardized to the age distribution of the cohort in 1995 
b Weight (kg)/height (m)2. 
c Weight (kg)/height (m). 
 
  
  
 
3
4
Table 2. Associations Between Measures of Body Size and Endometrial Cancer Risk in the Black Women’s Health Study, 1995–2013 
    Age Adjusteda  Multivariable Adjustedb 
Variable Cases Person-Years 
Incidence 
Ratec 
IRR 95% CI 
 
IRR 95% CI 
Body mass indexd,e         
     <25 45 206,678 21.8 1.00 Referent  1.00 Referent 
     25–29 64 210,619 30.4 1.03 0.71, 1.51  1.00 0.67, 1.48 
     ≥30 163 241,036 67.6 2.28 1.64, 3.17  1.88 1.27, 2.78 
          30–34 61 126,246 48.3 1.56 1.06, 2.31  1.49 0.97, 2.30 
          35–39 44 62,818 70.0 2.41 1.58, 3.66  2.16 1.34, 3.49 
          ≥40 58 51,972 111.6 4.34 2.93, 6.43  3.60 2.24, 5.78 
          Ptrend     <0.0001   <0.0001 
         
Quartile of weight-to-height  
   ratiod,f 
     
 
  
     1 (<39.7) 30 164,928 18.2 1.00 Referent  1.00 Referent 
     2 (39.7–45.7) 51 164,343 31.0 1.32 0.84, 2.07  1.36 0.86, 2.17 
     3 (45.8–53.7) 63 163,871 38.4 1.48 0.96, 2.30  1.45 0.91, 2.33 
     4 (≥53.8) 128 163,997 78.1 3.25 2.18, 4.86  2.83 1.77, 4.53 
     Ptrend     <0.0001   <0.0001 
         
Waist circumference, cmg         
     <80 61 242,868 25.1 1.00 Referent  1.00 Referent. 
      80–87 45 111,403 40.4 1.20 0.82, 1.77  1.01 0.67, 1.52 
     ≥88 119 164,147 72.5 1.91 1.40, 2.62  1.09 0.75, 1.58 
     Ptrend     <0.0001   0.86 
         
Quartile of hip circumference,  
   cmg 
     
 
  
     1 (<91.4) 37 137,903 26.8 1.00 Referent.  1.00 Referent 
     2 (91.4–101.6) 43 169,884 25.3 0.68 0.44, 1.05  0.64 0.41, 1.00 
     3 (101.7–109.2) 37 102,711 36.0 0.80 0.50, 1.26  0.67 0.41, 1.09 
     4 (≥109.3) 124 159,137 77.9 1.64 1.13, 2.39  0.86 0.55, 1.36 
     Ptrend     <0.0001   0.96 
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Table 2. continued 
    Age Adjusteda  Multivariable Adjustedb 
Variable Cases Person-Years 
Incidence 
Ratec 
IRR 95% CI 
 
IRR 95% CI 
Waist-to-hip ratiog         
     <0.80 118 312,877 37.7 1.00 Referent.  1.00 Referent 
     0.80–0.84 42 91,813 45.7 1.09 0.77, 1.55  1.04 0.73, 1.48 
     ≥0.85 81 162,822 49.7 1.21 0.91, 1.60  1.06 0.79, 1.42 
     Ptrend     0.17   0.65 
         
Quartile of waist-to-height  
   ratiog 
     
 
  
     1 (<0.435) 27 128,275 21.0 1.00 Referent  1.00 Referent 
     2 (0.435–0.485) 44 130,319 33.8 1.25 0.77, 2.02  1.20 0.73, 1.95 
     3 (0.486–0.553) 45 128,494 35.0 1.07 0.66, 1.73  0.84 0.50, 1.40 
     4 (≥0.554) 108 129,855 83.2 2.25 1.46, 3.46  1.18 0.72, 1.95 
     Ptrend     <0.0001   0.70 
         
Quartile of height, cmh         
     1 (<160) 74 195,018 37.9 1.00 Referent.  1.00 Referent 
     2 (160–163) 43 95,340 45.1 1.22 0.84, 1.79  1.16 0.79, 1.69 
     3 (164–168) 74 178,488 41.5 1.14 0.82, 1.57  0.99 0.71, 1.37 
     4 (≥169) 82 192,401 42.6 1.31 0.95, 1.79  1.01 0.73, 1.40 
     Ptrend     0.13   0.87 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio.  
a Stratified jointly by age and study period. 
b Stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, estrogen-only 
female menopausal hormone use, estrogen plus progestin female menopausal hormone use, smoking status, type 2 diabetes, 
hypertension, hypercholesterolemia, and vigorous physical activity. 
c Per 100,000 person-years. 
d Additionally adjusted for waist circumference. 
e Weight (kg)/height (m)2. 
f Weight (kg)/height (m). 
g Additionally adjusted for body mass index. 
h Additionally adjusted for weight. 
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Table 3. Associations of Early Adulthood Obesity and Change in Weight Since Early Adulthood With Endometrial Cancer Risk, Black 
Women’s Health Study, 1995–2013 
    Age Adjusteda  Multivariable Adjustedb 
Variable Cases Person-Years 
Incidence 
Ratec 
IRR 95% CI 
 
IRR 95% CI 
BMI age 18 yearsd,e         
     <18.5 41 111,513 36.8 0.82 0.58, 1.15  0.85 0.60, 1.20 
     18.5–24.9 167 430,407 38.8 1.00 Referent  1.00 Referent 
     25.0–29.9 27 68,531 39.4 1.31 0.87, 1.97  1.11 0.73, 1.67 
     ≥30.0 22 29,505 74.6 2.69 1.72, 4.22  1.99 1.26, 3.15 
     Ptrend     <0.0001   0.003 
         
Quartile of weight-to- 
   height ratio age 18 yearsd,f 
     
 
  
     1 (<31.6) 60 160,853 37.3 1.00 Referent   1.00 Referent 
     2 (31.6–34.1) 61 158,417 38.5 1.13 0.79, 1.61  1.13 0.79, 1.62 
     3 (34.2–38.2) 55 160,690 34.2 1.12 0.78, 1.62  1.07 0.74, 1.55 
     4 (≥38.3) 81 160,013 50.6 1.98 1.41, 2.77  1.64 1.16, 2.32 
     Ptrend     <0.0001   0.02 
         
Change in weight from  
   age 18 years to  
   present, kgg 
     
 
  
     <–5 5 12,021 41.6 2.38 0.84, 6.77  2.06 0.72, 5.89 
     -5–4 12 74,596 16.1 1.00 Referent  1.00 Referent 
     5–14 31 176,381 17.6 0.92 0.47, 1.80  0.99 0.51, 1.95 
     15–24 69 183,350 37.6 1.57 0.84, 2.91  1.70 0.86, 3.33 
     25–34 57 106,059 53.7 1.97 1.05, 3.70  1.83 0.89, 3.77 
     35–44 33 53,753 61.4 2.18 1.12, 4.26  1.58 0.72, 3.47 
     ≥45 60 48,528 123.6 4.50 2.40, 8.43  2.30 1.03, 5.12 
     Ptrend     <0.0001   0.31 
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Table 3. continued 
Abbreviations: BMI, body mass index; CI, confidence interval; IRR, incidence rate ratio. 
a Stratified jointly by age and study period. 
b Stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, estrogen-only 
female menopausal hormone use, estrogen plus progestin female menopausal hormone use, smoking status, type 2 diabetes, 
hypertension, hypercholesterolemia, and vigorous physical activity. 
c Per 100,000 person-years. 
d Additionally adjusted for waist circumference. 
e Weight(kg)/ height(m)2.. 
f Weight (kg/)/height (m). 
g Additionally adjusted for body mass index. 
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Table 4. Associations of Type 2 Diabetes, Hypertension, and Hypercholesterolemia With Endometrial 
Cancer Risk in the Black Women’s Health Study, 1995–2013 
 
   Age Adjusteda 
 Multivariable 
Adjustedb 
Variable Cases 
Person-
Years 
Incidence 
Ratec 
IRR 95% CI 
 
IRR 95% CI 
Type 2 diabetesd         
     Never 218 618,332 35.3 1.00 Referent  1.00 Referent 
     Ever 57 47,417 120.2 1.60 1.18, 2.17  1.52 1.04, 2.21 
Hypertensione         
     Never 131 477,082 27.5 1.00 Referent  1.00 Referent 
     Ever 144 188,666 76.3 1.29 0.99, 1.67  1.02 0.78, 1.33 
Hypercholesterolemiaf         
     Never 181 511,391 35.4 1.00 Referent  1.00 Referent 
     Ever 94 154,357 60.9 0.87 0.67, 1.13  0.92 0.67, 1.27 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio. 
a Stratified jointly by age and study period. 
b Stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral 
contraceptive use, estrogen-only female menopausal hormone use, estrogen plus progestin female 
menopausal hormone use, smoking status, type 2 diabetes, body mass index, vigorous physical activity, 
statin use, and metformin use. 
c Per 100,000 person-years. 
d Additionally adjusted for waist circumference, hypertension, and hypercholesterolemia. 
e Additionally adjusted for waist circumference, type 2 diabetes, and hypercholesterolemia. 
f Additionally adjusted for waist circumference, type 2 diabetes, and hypertension. 
 
 39 
3 Reproductive Factors and Endometrial Cancer Risk in U.S. Black 
Women 
 
3.1 Abstract 
Introduction: Little is known about whether reproductive risk factors for 
endometrial cancer among black women, whose incidence and mortality differ 
from white women, are similar to those among white women. We investigated 
associations of reproductive factors with endometrial cancer in the Black 
Women’s Health Study.  
 
Methods: Every 2 years from 1995 to 2013, 47,555 participants with intact uteri 
completed questionnaires on reproductive and medical history, lifestyle factors, 
and exogenous hormone use. Cases of endometrial cancer were self-reported 
and confirmed by medical records or cancer registries when available. We used 
Cox proportional hazards regression to estimate multivariable incidence rate 
ratios (IRR) and 95% confidence intervals (CI). 
 
Results: During 689,501 person-years of follow-up, we identified 300 incident 
cases of endometrial cancer. The strongest associations were with early age at 
menarche (<11 vs. 12–13 years: IRR: 1.82, 95% CI: 1.31, 2.52), later age at first 
birth (≥30 vs. <20 years: IRR: 0.26, 95% CI: 0.13, 0.50), and lifetime number of 
menstrual cycles (≥500 vs. <300: IRR=1.95, 95% CI: 1.17, 3.27). Parous women 
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were 0.77 times as likely as nulliparous women to develop endometrial cancer 
(95% CI: 0.57, 1.05), but there was little evidence of a dose-response 
relationship. In stratified analyses, both early and late ages at menarche were 
associated with higher risk of endometrial cancer among premenopausal women; 
longer-term breastfeeding was associated with increased risk among obese 
women.  
 
Conclusion Associations between reproductive factors and endometrial cancer 
among black women were generally consistent with those in previous studies of 
white women. Novel findings in analyses stratified by menopausal status and 
obesity require confirmation in other studies. 
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3.2 Introduction 
 Given the central role of estrogen and progesterone in the etiology of 
endometrial cancer,26 one would expect a woman’s reproductive history to 
substantially influence her risk. Reproductive factors that consistently have been 
shown to increase the risk of endometrial cancer include early age at 
menarche,15,25,27,34,48,51 late age at menopause,15,25,27,34,43,48,51 greater number of 
lifetime menstrual cycles,34,42,48 nulliparity,7,15,21,25,27–29,34,38,40,42,48,51 early age at 
last birth,22,25,27–29,34 and a greater number of years since last birth.15,38,40 
Associations between endometrial cancer and factors such as age at first 
birth,7,15,25,27–29,34,38,40,42,48 breastfeeding,7,15,42,48 and history of infertility 4,7,8,18,34 
have been inconsistent across studies.  
Because there are few data on reproductive risk factors for endometrial 
cancer among black women,12 it is not known to what extent associations of 
endometrial cancer with such factors estimated in white women apply to black 
women. The prevalence of several potential risk factors differs appreciably 
between black and white women: e.g., parity and early births are more 
common,31,32 and breast feeding is less common,9,10 among black women. We 
therefore evaluated the association between several reproductive factors and risk 
of endometrial cancer in a U.S. prospective cohort study of black women.   
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3.3 Methods 
3.3.1 Data Source 
 The Black Women’s Health Study (BWHS) is a cohort of 59,001 self-
identified U.S. black women.41 In 1995, women aged 21–69 were recruited from 
the subscription list of Essence magazine, black professional organizations, and 
friends and relatives of study participants. Data on demographic factors, 
reproductive history, smoking, alcohol consumption, anthropometric 
measurements, health history, and medication use were collected via postal 
questionnaire at baseline and updated on biennial follow-up questionnaires. 
Follow-up is complete for 87% of potential person-years through 2013. The study 
was approved by the institutional review board of Boston University, Boston, 
Massachusetts. 
At baseline, we excluded women with a history of uterine cancer (n=258), 
cervical cancer (n=82), or hysterectomy (n=10,659) or who did not return at least 
1 questionnaire after baseline (n=447). We followed the remaining 47,555 women 
for incident endometrial cancer from 1995 through 2013.  
 
3.3.2 Outcome 
Participants reported new diagnoses of “uterine cancer” on biennial follow-
up questionnaires from 1997 through 2013. In 1995 and 2011, participants were 
not asked specifically about uterine cancer but were asked to report any “other 
serious illness.” Potential cases were also identified through records from state 
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cancer registries in 24 states where 95% of participants lived and death 
certificate data obtained from the National Death Index (NDI). There were a total 
of 367 potential cases from all sources. Eighteen women subsequently reported 
that they had a condition other than uterine cancer when contacted for 
permission to release medical records. Of the remaining 349 potential cases, we 
obtained medical records, cancer registry data, and/or death certificate data for 
249 (71%). Of these, 231 (93%) were confirmed as either endometrial cancer 
(n=213) or uterine sarcoma (n=18). Because the confirmation rate was high, we 
accepted the remaining unverified cases as cases of incident endometrial 
cancer. Thus, after the exclusion of uterine sarcomas, there were a total of 300 
cases of endometrial cancer (213 confirmed and 87 unverified) available for 
analysis. Among the confirmed cases, International Classification of Diseases for 
Oncology (ICD-O) codes allowed further classification of 182 cases according to 
major histological types; 131 (72%) were type I, 30 (16%) were type II, and 21 
(12%) were type III (Appendix 2, Table 16).50 
 
3.3.3 Exposures  
Women reported their age at menarche on the baseline questionnaire in 
1995. Data on age at first birth, parity, gynecologic surgeries (hysterectomy, 
bilateral oophorectomy, unilateral oophorectomy), menopausal status, type of 
menopause (natural, surgical, and medical), and age at menopause were 
collected at baseline and updated on subsequent follow-up questionnaires. 
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Women were considered postmenopausal if they reported cessation of menstrual 
cycles for ≥12 months, reported bilateral oophorectomy, or if they were ≥57 years 
of age and reported that their menopausal status was obscured due to hormone 
use. Women who did not report cessation of menstrual cycles for ≥12 months or 
bilateral oophorectomy or who were <43 years of age and reported that their 
menopausal status was obscured by hormone use were considered 
premenopausal. Participants reported the total duration of lactation from all births 
at baseline and updated duration of lactation on the 1997–2005 and 2011 
questionnaires. Infertility was reported in 1995, 2007, and 2011 as “ever tried to 
become pregnant for more than one year without success,” along with the 
participant’s age at that time. In 1999 and 2001, we asked women if they had 
ever been diagnosed with polycystic ovary syndrome (PCOS) and year of first 
diagnosis. The lifetime number of menstrual cycles for premenopausal women 
was calculated as [current age – age at menarche]*13 - [parity*9] - [total months 
of breastfeeding] - [total duration of oral contraceptive use]. For postmenopausal 
women, age at menopause was substituted for current age.   
 
3.3.4 Covariates 
 At baseline and on the biennial questionnaires, participants reported their 
height and weight (with which we computed body mass index [BMI], kg/m2) and 
diagnosis of diabetes, diagnosis of uterine leiomyomata, oral contraceptive use, 
female menopausal hormone use, alcohol use, smoking status, state of 
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residence, and breastfeeding. Weight at age 18 was assessed at baseline and 
used to calculate BMI at age 18. Data on vigorous exercise (hours/week) was 
ascertained on all questionnaires with the exception of 2003 and 2005. Marital 
status was reported in 1995, 1997, 1999 and 2003. Participants reported their 
education level at baseline, household income in 2003, and parental and 
partner/spouse education in 2009.  
 
3.3.5 Data Analysis 
 
 The analysis included 300 incident cases of endometrial cancer identified 
between 1995 and 2013, excluding eighteen disconfirmed by medical records. 
Participants contributed person-time from baseline until the diagnosis of 
endometrial cancer or one of the following censoring events: diagnosis of a non-
epithelial uterine cancer (n=52), hysterectomy (n=7,564), loss-to-follow-up 
(n=13,108), or the end of follow-up in 2013, whichever came first. We calculated 
crude incidence rates and incidence rate ratios (IRRs) for all categories of 
exposure compared with the reference category. Cox proportional hazards 
regression models13 stratified by age and questionnaire cycle were used to 
calculate adjusted IRRs and 95% confidence intervals (CI). The Andersen-Gill 
data structure2 was used to accommodate time-varying covariates. Missing 
values were imputed by carrying forward the last observation. We modeled the 
median value of each exposure category as a continuous variable and calculated 
a Wald test statistic to test for linear trend. Departures from proportional hazards 
 46 
were assessed by comparing models with and without interaction terms between 
exposures and each of the time scales (age and questionnaire cycle) using the 
likelihood ratio test.  
Exposures were categorized as follows: age at menarche (<11, 11, 12–13, 
≥14 years), parity (nulliparous, parous), number of live- or still-births (1, 2, 3, ≥4 
births), age at first birth (<20, 20–24, ≥25 years), age at last birth (<25, 25–29, 
30–34, ≥35 years), years since last birth (<20, 20–29, 30–39, ≥40 years), 
breastfeeding (never, ever), lifetime duration of breastfeeding (0, 1–11, ≥12 
months), estimated number of lifetime menstrual cycles (<300, 300–399, 400–
499, ≥500), age at natural menopause (<45, 45–49, 50–45, ≥55 years), history of 
diagnosis of PCOS (no, yes), and history of infertility (no, yes). 
 To control for potential confounding, we adjusted for known or suspected 
risk factors for endometrial cancer. These covariates included participant 
education (less than high school, high school diploma, some college, college 
degree, postgraduate), marital status (single, married, 
separated/divorced/widowed), oral contraceptive use (never, former, current), 
use of estrogen-only and estrogen plus progesterone female menopausal 
hormones (never, former, current), smoking status (never, former, current), BMI 
(<25, 25–29, 30–34, 35–39, ≥40 kg/m2), vigorous physical activity (0, 1–4, ≥5 
hours/week), as well as age at menarche (<11, 11, 12–13, ≥14 years), number of 
births (0, 1, 2, 3, ≥4), and menopausal status (premenopausal vs. 
postmenopausal). Analyses of exposures involving the timing of births and 
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breastfeeding were restricted to parous women and adjusted for the above 
variables plus age at first birth (in the categories listed above).  
 Both obesity and menopause have large effects on the hormonal 
environment of the endometrium.46 We therefore decided a priori to repeat 
analyses stratified by menopausal status (premenopausal vs. postmenopausal) 
and by current body mass index (<30 vs. ≥30 kg/m2). We created interaction 
terms between exposures of interest and the stratification terms, comparing 
models with and without these terms using the likelihood ratio test. We repeated 
analyses separately for type I and type II/III endometrial cancers, censoring all 
other incident cases. Additionally, we analyzed the data using only confirmed 
cases, censoring all other incident cases, in order to evaluate the impact of the 
inclusion of unverified cases on our results. 
 All analyses were conducted using SAS software, version 9.4 (SAS 
Institute, Inc., Cary, North Carolina). 
3.4 Results 
 Characteristics of the cohort at baseline in 1995 are given in Table 5.  
Mean age was 36.6 years, 39% of women were nulliparous and 10% were 
postmenopausal. Mean length of follow-up was 14.5 years. 
 After control for other variables (Table 6), earlier age at menarche was 
associated with an increased risk of endometrial cancer: compared with women 
who experienced menarche at age 12–13 years, the IRR for women with age at 
menarche <11 years was 1.82 (95% CI: 1.31, 2.52). The IRR for parous women 
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compared with nulliparous women was 0.77 (95% CI: 0.57, 1.05). The decrease 
in risk seen among parous women was only slightly diminished when history of 
infertility was added to the model (data not shown). There was little evidence of a 
dose-response relationship between number of births and endometrial cancer 
risk. Women who had their first birth at age ≥30 years had a reduced risk of 
endometrial cancer compared with women who had their first birth at less than 20 
years (IRR=0.26, 95% CI: 0.13, 0.50, Ptrend=0.0004). The inverse association with 
age at last birth and positive association with years since last birth were no 
longer apparent after control for age at first birth. Breastfeeding was not 
associated with endometrial cancer risk. There was a positive monotonic 
relationship between number of menstrual cycles and endometrial cancer risk 
(Ptrend=0.005); the IRR for ≥500 menstrual cycles compared with <300 menstrual 
cycles was 1.95 (95% CI: 1.17, 3.27). The IRR for age at natural menopause ≥55 
years compared with <45 years was 1.45 (95% CI: 0.70, 3.02) but there was no 
clear trend with increasing age (Ptrend=0.47). Additionally, risk was higher among 
women who reported a history of infertility (IRR=1.26, 95% CI: 0.90, 1.75) or 
diagnosis of PCOS (IRR=1.86, 95% CI: 0.76, 4.55), although the latter IRR was 
based on only 5 cases. 
 Results were similar according to menopausal status except for two 
factors: age at menarche and age at first birth (Table 7). Among postmenopausal 
women, increasing age at menarche was inversely related with endometrial 
cancer risk (Ptrend=0.04). In contrast, both early and late ages at menarche were 
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associated with increased cancer risk in premenopausal women. The IRR for age 
at menarche <11 years compared with 12–13 years was 2.98 (95% CI: 1.69, 
5.25), and for ≥14 years it was 2.79 (95% CI: 1.66, 4.69). Among premenopausal 
women, an age at first birth later than 25 years was associated with a lower risk 
of endometrial cancer relative to an age at first birth earlier than 20 years 
(IRR=0.32, 95% CI: 0.15, 0.68), but there was little association in 
postmenopausal women. 
 Results also varied by obesity status (Table 8). Early age at menarche 
appeared to be more strongly related to endometrial cancer risk among obese 
women than non-obese women. For women with BMI ≥30 kg/m2, the IRR for age 
at menarche ≤11 years versus 12–13 years was 2.04 (95% CI: 1.38, 3.02); 
among women with BMI <30 kg/m2, the IRR was 1.47 (95% CI: 0.79, 2.76). 
Breastfeeding was associated with decreased risk of endometrial cancer among 
normal- or overweight women, but with increased risk among obese women. The 
IRR for breastfeeding ≥12 months compared with none was 0.51 (95% CI: 0.22, 
1.16) among non-obese women and 2.06 (95% CI: 1.19, 3.55) among obese 
women.  
 As shown in Table 9, there was an inverse relationship between number 
of births and type I (Ptrend=0.001) but not type II/III (Ptrend=0.57) tumors. The IRRs 
for ≥4 births vs. 1 were 0.31 (95% CI: 0.15, 0.64) for the association with type I 
endometrial cancer and 1.52 (95% CI: 0.51, 4.54) for the association with type 
II/III tumors. Also, while the IRR for breastfeeding ≥12 months was 2.58 (95% CI: 
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1.05, 6.35) for the association with types II and III cancers, but 1.16 (95% CI: 
0.52, 2.57) for type I cancers. Associations of other risk factors with the two 
histologic subtypes appeared similar to one another (Appendix 2, Table 17).  
 We detected deviations from proportional hazards (interactions with age 
and study period) for age at menarche, and ages at first and last birth 
(interactions with age). This is likely the result of differences observed between 
pre- and postmenopausal women for these variables (Table 7). In 
premenopausal women, the association between age at menarche and 
endometrial cancer appeared U-shaped, while there was an inverse trend in 
postmenopausal women. Late age at first birth was inversely associated with risk 
in premenopausal women, but the magnitude of any protective effect in 
postmenopausal women was small. Estimated IRRs were imprecise for age at 
last birth, but the point estimates were consistent with a decreasing trend in 
postmenopausal women. There did not appear to be any relationship to risk in 
premenopausal women. No violations of proportional hazards were observed for 
the other variables. 
 Most associations were little changed when we limited analysis to 
confirmed cases (Appendix 2, Table 18). The positive association between 
longer durations of breastfeeding and endometrial cancer remained, but was 
slightly weaker. 
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3.6 Discussion 
 The results of the present study suggest that early menarche, nulliparity, 
greater number of menstrual cycles, and later age at menopause are associated 
with increased risk of endometrial cancer in black women. Among characteristics 
associated with childbearing, late age at first birth was strongly associated with 
decreased endometrial cancer risk, while number of births, age at last birth and 
years since last birth were weakly associated with risk. Age at menarche was 
strongly related to endometrial cancer risk in premenopausal women, with higher 
risks seen for both early and late menarche. In postmenopausal women, there 
was an increased risk with earlier age at menarche but not late menarche. 
Associations of age at menarche and breastfeeding with endometrial cancer risk 
appeared to vary by obesity status. The increase in risk was similar in non-obese 
women with early and late ages at menarche, but not in obese women, while 
breastfeeding appeared to be associated with decreased risk in non-obese 
women but increased risk in obese women. Since many comparisons were 
made, the novel results by menopausal- and obesity status may have occurred 
by chance. 
The association between number of menstrual cycles and endometrial 
cancer agrees with current scientific literature regarding the etiology of these 
cancers.34,42,48 The “unopposed estrogens hypothesis,” as summarized by Key 
and Pike,26 posits that endometrial cancers develop due to mutations that 
accumulate when endometrial tissue undergoes repeated cycles of proliferation. 
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The number of menstrual cycles is proportional to the number of proliferative 
cycles, so a strong association would be expected. Factors that reduce the 
number of ovulatory cycles, such as late age at menarche and parity, may also 
be associated with lower levels of androgens and estrogens and/or higher levels 
of progesterone.3,14,17,30,49 Therefore, the association between a greater number 
of menstrual cycles and endometrial cancer may also be explained by a tumor-
promoting hormonal milieu. 
Associations also would be expected for factors that influence the number 
of ovulatory cycles, such as age at menarche and menopause, parity, and 
breastfeeding. Previous studies15,25,27,34,43,48,51 have found evidence for 
associations between age at menarche and endometrial cancer risk, with a trend 
for lower risk with later menarche. In addition to altered levels of endogenous 
hormones, low birth weight is associated with early age at menarche,16 which, in 
turn, has been linked to adult obesity,20,35,47 and type 2 diabetes.24 It may 
therefore be a marker for early-life metabolic changes which increase 
subsequent endometrial cancer risk. We found that the expected inverse trend 
for age at menarche held among postmenopausal women. However, among 
premenopausal women, endometrial cancer rates were elevated among those 
with early (<11 years) and late (≥14 years) ages at menarche. Studies in 
French11 and Japanese23 populations found that, while overall age at menarche 
was decreasing over time in these populations, the interval between onset of 
menarche and the beginning of regular cycling was lengthening. In both 
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populations, this interval was longer in women with later age at menarche. The 
reasons for this are unclear. However, if similar trends are occurring in U.S. black 
women, the positive association between late age at menarche and endometrial 
cancer we found in premenopausal women, if not a chance finding, may be 
because they experience a greater number of anovulatory cycles. 
Inverse associations with endometrial cancer risk have been reported 
consistently for increasing number of births.7,15,22,25,27–29,34,38–40,42,48 Most,27–29,40,42 
but not all,7,34 prior studies have found inverse associations with age at last birth. 
While several studies have reported inverse associations with age at first 
birth,6,22,27,39,48 one reported a strong positive association42 and many have found 
no association.28,29,34,37,40,42 Three studies have found increasing risk with 
increasing time since last birth15,38,40 with one finding no association.7 
Differentiating between the effects of these factors is difficult because of the high 
degree of collinearity between variables, including age, and studies have varied 
in the extent to which they have tried to model these factors together. Multiple 
mechanisms have been suggested to explain the associations of endometrial 
cancer with the number and timing of births. Reported changes in ovarian 
hormone levels following the first birth,7,25,28,40 exposure to high levels of 
progesterone during pregnancy25,28,38,48 and reduction in the overall number of 
ovulatory cycles by pregnancy22,48 would be expected to reduce the rate of 
malignant transformation of endometrial cells. Precancerous or cancerous cells 
may be eliminated by mechanical shedding during parturition15,25,28,38,40 or by 
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apoptosis during involution.25 Additionally, women who give birth later in life are 
less likely to experience anovulatory cycles as they approach menopause.7,25,28 
Some studies have found that a history of breastfeeding is protective 
against endometrial cancer,42,48 while others have found little association.7,15 
During lactation, levels of estrogen and progesterone are low,33 resulting in 
reduced exposure of the endometrium to unopposed estrogens. In our main 
analysis, there was little association. However, when we stratified by BMI, 
breastfeeding was associated with reduced risk among women with low or 
moderate BMI but with increased risk in breastfeeding women with high BMI. We 
are not aware of other studies that have examined the risk associated with 
breastfeeding stratified by BMI. One plausible mechanism for this finding is that 
adipose tissue may become an important source of estrogens during the period 
of lactational amenorrhea, similar to the situation in postmenopausal women. In 
the absence of adequate levels of progesterone, the endometria of obese women 
may continue to undergo proliferative cycles while those of non-obese women do 
not. Alternatively, a study of BWHS participants found that, while lactation was 
associated with weight loss over 8 years among women who were not obese pre-
pregnancy, it was associated with weight gain among women who were obese 
prepregnancy.36 Such weight gain, which was more strongly associated with 
long-term lactation,36 would be expected to increase endometrial cancer risk. Our 
cohort has few women with an extensive history of breastfeeding, and time-
varying BMI may not accurately reflect a woman’s BMI at the time of 
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breastfeeding. This result must therefore be interpreted cautiously in the absence 
of confirmation by other studies. 
A recent meta-analysis of five studies found that women diagnosed with 
PCOS had nearly three times the risk of endometrial cancer compared with 
women who had not been diagnosed.19 Our results, based on only five cases, 
were consistent with a positive association. The high levels of unopposed 
estrogens, luteinizing hormone (LH), and insulin and low levels of sex hormone 
binding globulin (SHGB) found among women with PCOS may all contribute to 
increased risk.45 Some prior studies have found a higher risk of endometrial 
cancer among women with a history of infertility,4,18 while others did not.7,34 Our 
results are consistent with the latter studies. Escobedo and colleagues found that 
the increase in risk was restricted to women diagnosed with ovarian problems, 
and hypothesized that exposure to unopposed estrogens via anovulation was the 
cause.18  
Researchers have divided endometrial cancers into three main histological 
types.5 The more common type I tumors were conceptualized as being hormone 
responsive, better differentiated, and having a better prognosis than types II and 
III cancers. Due to their rarity (about 10–20% of all endometrial cancers1), little is 
known about risk factors for types II and III endometrial cancer. Recently two 
large studies compared associations of the three types with established risk 
factors. Setiawan et al. found that types I, II, and III endometrial cancer had 
similar risk factors.44 Brinton found similarities as well, although women with 
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types II and III cancers were more likely to have high parity.6 We had too few 
type II and III cases to draw firm conclusions about the associations of the 
reproductive risk factors with these subtypes, and the appropriateness of 
grouping them together is not established. However, grouping all cases together 
may have contributed to the lack of an observed relationship of number of births 
that was seen with restriction to type I cancers only. Furthermore, the increase in 
risk we observed among women with longer lifetime durations of breastfeeding 
appeared to be confined to the more aggressive subtypes. 
Strengths of our study include its prospective design and high participation 
rates over 18 years of follow-up. We collected data on a large number of 
variables related to menstrual and reproductive history, and were able to control 
for a large number of potential confounders including obesity and use of oral 
contraceptives and menopausal estrogen use. 
Among the limitations of our study was the use of self-reported exposure 
data, which could have resulted in nondifferential misclassification of 
reproductive factors. The overall effect of nondifferential misclassification is 
expected to be towards the null for the extreme categories of exposure. We 
lacked histologic data for a large number of cases, and the small numbers of 
more aggressive cancer subtypes in this study resulted in imprecise estimates. 
We cannot exclude the possibility that BWHS participants differ from the general 
population of U.S. black women in ways that may limit the generalizability of 
these results. 
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In summary, the present study suggests that, consistent with previous 
results in white women, the number of menstrual cycles and factors that 
influence menstrual cycling increase the risk of endometrial cancer among black 
women. The relatively large proportion of type II and III cancers may have 
influenced our lack of evidence of an inverse trend with a greater number of 
births. Novel findings of an association of late menarche with increased risk 
among premenopausal women and breastfeeding with increased risk among 
obese women require confirmation in future studies. 
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Table 5. Age-Standardized Baseline Characteristicsa of 47,555 Participants in the 
Black Women’s Health Study, 1995 
Age in 1995, years, mean (SD) 36.6 (9.8) 
Education, years, mean (SD) 14.8 (1.8) 
Marital status  
     Single, % 38.8 
     Married/living together, % 38.4 
     Separated/Divorced/Widowed, % 21.8 
Age at menarche, years, mean (SD) 12.3 (1.6) 
Estimated number of menstrual cycles, mean (SD) 238.8 (118.4) 
History of infertility, % 8.9 
Parity  
     Nulliparous, % 39.3 
     1–2, % 43.6 
     ≥3, % 17.0 
Ever breastfed, %b 42.5 
Postmenopausal, % 9.8 
Age at menopause, years, mean (SD) 47.8 (5.8) 
Body mass index, kg/m2 27.7 (6.7) 
Vigorous physical activity, hours/week  
     0, % 28.9 
     1–4, % 51.7 
     ≥5, % 13.7 
Ever use of oral contraceptives, % 85.5 
Ever use of estrogen-only female hormones, % 1.4 
Ever use of estrogen plus progestin female hormones, % 3.5 
Abbreviations: SD, standard deviation. 
a Values are standardized to the age distribution of the study population. 
b Among women parous at baseline. 
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Table 6. Incidence Rate Ratios for Endometrial Cancer According to Reproductive Factors 
     Age Adjusteda  Multivariable Adjustedb 
Exposure Cases 
Person-
Years 
Ratec 
 
IRR 95% CI 
 
IRR 95% CI 
Age at menarche, years          
     <11 53 76,923 68.9  2.17 1.57, 2.99  1.82 1.31, 2.52 
     11 58 114,079 50.8  1.53 1.12, 2.10  1.41 1.03, 1.93 
     12–13 126 363,526 34.7  1.00 Referent  1.00 Referent 
     ≥14 61 131,796 46.3  1.19 0.88, 1.62  1.23 0.90, 1.67 
     Ptrend      0.002   0.04 
          
Parity          
     Nulliparous 74 212,512 34.8  1.00 Referent  1.00 Referent 
     Parous 225 473,064 47.6  0.72 0.55, 0.95  0.77 0.57, 1.05 
          
Number of birthsd,e          
     1 67 175,164 38.2  1.00 Referent  1.00 Referent 
     2 66 166,860 39.6  0.82 0.58, 1.15  0.71 0.50, 1.01 
     3 47 80,554 58.3  1.04 0.71, 1.53  0.81 0.54, 1.21 
     ≥4 45 50,486 89.1  1.15 0.77, 1.71  0.74 0.48, 1.15 
     Ptrend      0.36   0.27 
          
Age at first birth, yearsd          
     <20 88 127,552 69.0  1.00 Referent  1.00 Referent 
     20–24 79 146,001 54.1  0.78 0.57, 1.06  0.83 0.60, 1.15 
     25–29 47 106,160 44.3  0.78 0.54, 1.11  0.85 0.57, 1.26 
     ≥30 11 87,845 12.5  0.25 0.13, 0.47  0.26 0.13, 0.50 
     Ptrend      <0.0001   0.0004 
          
Age at last birth, yearsd,e,          
    <25 73 126,071 57.9  1.00 Referent  1.00 Referent 
     25–29 78 134,031 58.2  1.00 0.73, 1.38  1.18 0.79, 1.74 
     30–34 42 12,096 33.6  0.60 0.41, 0.88  0.87 0.53, 1.43 
     ≥35 25 77,444 32.3  0.51 0.32, 0.80  0.79 0.44, 1.42 
     Ptrend      0.0002   0.43 
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Table 6. continued          
     Age Adjusteda  Multivariable Adjustedb 
Exposure Cases 
Person-
Years 
Ratec 
 
IRR 95% CI 
 
IRR 95% CI 
Years since last birthd,e,          
     <20 50 274,968 18.2  1.00 Referent  1.00 Referent 
     20–29 56 100,484 55.7  1.43 0.85, 2.40  0.98 0.57, 1.68 
     30–39 77 57,957 132.9  1.91 1.07, 3.41  1.03 0.53, 1.96 
     ≥40 35 22,149 158.0  1.75 0.86, 3.57  0.75 0.32, 1.75 
     Ptrend      0.04   0.46 
          
Breastfeedingd,e          
     No 139 253,648 54.8  1.00 Referent  1.00 Referent 
     Yes 86 219,416 39.2  0.85 0.65, 1.11  0.98 0.74, 1.31 
          <12 months 58 161,527 35.9  0.79 0.58, 1.08  0.92 0.67, 1.26 
          ≥12 months 27 52,733 51.2  0.99 0.66, 1.51  1.17 0.75, 1.83 
          
Lifetime number of  
   menstrual cycles 
   
      
     <300 54 341,421 15.8  1.00 Referent  1.00 Referent 
     300–399 70 184,531 37.9  1.35 0.88, 2.05  1.15 0.76, 1.75 
     400–499 115 130,626 88.0  1.89 1.22, 2.94  1.53 0.99, 2.37 
     ≥500 58 28,576 203.0  3.07 1.88, 5.00  1.95 1.17, 3.27 
     Ptrend      <0.0001   0.004 
          
Age at natural  
   menopause, years 
   
 
  
 
  
     <45 12 22,960 52.3  1.00 Referent  1.00 Referent 
     45–49 38 46,155 82.3  1.44 0.72, 2.84  1.45 0.73, 2.89 
     50–54 64 64,053 99.9  1.32 0.68, 2.55  1.32 0.67, 2.56 
     ≥55 28 19,161 146.1  1.65 0.80, 3.39  1.45 0.70, 3.02 
     Ptrend      0.26   0.47 
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Table 6. continued     
     Age Adjusteda  Multivariable Adjustedb 
Exposure Cases 
Person-
Years 
Ratec 
 
IRR 95% CI 
 
IRR 95% CI 
History of infertility          
     No 254 626,155 40.6  1.00 Referent  1.00 Referent 
     Yes 46 36,385 72.6  1.19 0.87, 1.64  1.26 0.90, 1.75 
          
Ever diagnosis of PCOS          
     No 295 682,505 43.2  1.00 Referent  1.00 Referent 
     Yes 5 6,996 71.5  2.33 0.96, 5.66  1.86 0.76, 4.55 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio; PCOS, polycystic ovary syndrome. 
a Stratified jointly by age and study period. 
b Stratified by age and study period and adjusted for education, marital status, age at menarche, number of 
births, menopausal status, oral contraceptive use, estrogen-only female menopausal hormone use, 
estrogen plus progestin female menopausal hormone use, smoking status, body mass index, and vigorous 
physical activity. 
c Crude incidence rate per 100,000 person-years. 
d Restricted to parous women. 
e Additionally adjusted for age at first birth. 
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Table 7. Incidence Rate Ratios for Endometrial Cancer According to Reproductive Factors, Stratified by Menopausal Status 
 Premenopausal  Postmenopausal  
Exposure Cases Ratea IRRb 95% CI  Cases Ratea IRRb 95% CI Pinteraction 
Age at menarche,  
   years 
          
     <11 22 38.0 2.98 1.69, 5.25  25 152.6 1.34 0.86, 2.11  
     11 20 23.6 2.17 1.22, 3.86  34 133.5 1.25 0.84, 1.86  
     12–13 30 11.3 1.00 Referent  87 101.6 1.00 Referent  
     ≥14 29 31.8 2.79 1.66, 4.69  30 83.6 0.83 0.55, 1.26 0.009 
     Ptrend    0.83     0.04  
           
Age at first birth, yearsc           
     <20 31 39.2 1.00 Referent  51 117.7 1.00 Referent  
     20–24 24 26.1 0.79 0.45, 1.39  50 103.2 0.88 0.58, 1.33  
     ≥25 12 8.3 0.32 0.15, 0.68  42 96.8 0.90 0.56, 1.46 0.008 
     Ptrend    0.001     0.20  
           
Age at last birth,  
   yearsc,d 
          
     <25 12 34.5 1.00 Referent  19 93.9 1.00 Referent  
     25–29 15 26.6 1.02 0.44, 2.37  43 145.0 1.74 0.97, 3.11  
     30–34 10 16.9 0.74 0.28, 1.98  22 78.2 0.95 0.48, 1.92  
     ≥35 5 15.3 0.95 0.28, 3.25  15 77.9 0.92 0.42, 2.01 0.26 
     Ptrend    0.63     0.67  
Abbreviations: CI, confidence interval; IRR, incidence rate ratio. 
a Per 100,000 person-years. 
b Stratified by age and study period and adjusted for education, marital status, age at menarche, number of births, oral contraceptive 
use, estrogen-only female menopausal hormone use, estrogen plus progestin female menopausal hormone use, smoking status, body 
mass index, and vigorous physical activity. 
c Restricted to parous women. 
d Additionally adjusted for age at first birth. 
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Table 8. Incidence Rate Ratios for Endometrial Cancer According to Reproductive Factors, Stratified by Obesity 
 BMI <30 kg/m2  BMI ≥30 kg/m2 
Exposure Cases Ratea IRRb 95% CI  Cases Ratea IRRb 95% CI Pinteraction 
Age at menarche, years           
     <11 12 33.0 1.47 0.79, 2.76  41 102.7 2.04 1.38, 3.02  
     11 16 25.2 1.10 0.63, 1.91  41 82.7 1.61 1.09, 2.38  
     12–13 56 24.0 1.00 Referent  68 53.8 1.00 Referent  
     ≥14 34 37.0 1.38 0.90, 2.12  27 70.0 1.16 0.74, 1.82 0.24 
     Ptrend    0.62     0.005  
           
Age at first birth, yearsc           
     <20 31 43.5 1.00 Referent  57 104.2 1.00 Referent  
     20–24 33 37.6 1.00 0.59, 1.67  45 79.5 0.77 0.51, 1.16  
     ≥25 26 20.6 0.72 0.39, 1.34  30 45.3 0.58 0.35, 0.97 0.93 
     Ptrend    0.19     0.03  
           
Breastfeedingc,d           
     No 64 42.9 1.00 Referent  72 70.7 1.00 Referent  
     Yes 26 18.6 0.54 0.33, 0.88  60 77.2 1.49 1.03, 2.15  
          <12 months 19 18.5 0.58 0.34, 0.99  39 68.1 1.30 0.86, 1.95 0.005 
          ≥12 months 7 20.8 0.51 0.22, 1.16  20 108.2 2.06 1.19, 3.55  
Abbreviations: BMI, body mass index; CI, confidence interval; IRR, incidence rate ratio. 
a Per 100,000 person-years. 
b Stratified by age and study period and adjusted for education, marital status, age at menarche, number of births, menopausal status, 
oral contraceptive use, estrogen-only female menopausal hormone use, estrogen plus progestin female menopausal hormone use, 
smoking status, body mass index (continuous), and vigorous physical activity. 
c Restricted to parous women. 
d Additionally adjusted for age at first birth. 
 
  
  
6
9
Table 9. Incidence Rate Ratios for Subtypes of Endometrial Cancer According to Reproductive Factors 
 Type I  Type II/III 
 Case Ratea IRRb 95% CI  Case Ratea IRRb 95% CI 
Age at menarche,     
   years 
         
     <11 21 27.3 1.38 0.83, 2.28  10 13.0 1.84 0.87, 3.90 
     11 23 20.2 1.10 0.68, 1.78  8 7.0 1.08 0.48, 2.41 
     12–13 61 16.8 1.00 Referent  25 6.9 1.00 Referent 
     ≥14 26 19.7 1.12 0.70, 1.77  8 6.1 0.75 0.34, 1.67 
     Ptrend    0.63     0.13 
          
Number of birthsc,d          
     1 35 20.0 1.00 Referent  7 4.0 1.00 Referent 
     2 25 15.0 0.45 0.27, 0.77  14 8.4 1.77 0.68, 4.58 
     3 16 19.9 0.44 0.23, 0.82  9 11.2 1.63 0.56, 4.75 
     ≥4 13 25.8 0.31 0.15, 0.64  11 21.8 1.52 0.51, 4.54 
     Ptrend    0.001     0.57 
          
          
Breastfeedingc,d          
     No 53 20.9 1.00 Referent  24 9.5 1.00 Referent 
     Yes 36 16.4 1.25 0.80, 1.97  17 7.8 1.27 0.66, 2.46 
          <12 months 28 17.3 1.28 0.79, 2.07  8 5.0 0.88 0.38, 2.03 
          ≥12 months 8 15.2 1.16 0.52, 2.57  8 15.2 2.58 1.05, 6.35 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio. 
a Per 100,000 person-years. 
b Stratified by age and study period and adjusted for education, marital status, age at menarche, number of births, menopausal status, 
oral contraceptive use, estrogen-only female menopausal hormone use, estrogen plus progestin female menopausal hormone use, 
smoking status, body mass index, and vigorous physical activity. 
c Restricted to parous women. 
d Additionally adjusted for age at first birth. 
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4 Exogenous Hormone Use and Endometrial Cancer in U.S. Black 
Women 
 
4.1 Abstract 
Background: Studies of white women have reported lower endometrial cancer 
risk among oral contraceptive (OC) users, but higher risk among users of 
estrogen-only female menopausal hormones (FMH). Evidence for the association 
between estrogen plus progestin FMHs and endometrial cancer is more variable 
and dependent on the timing of progestin use. Few studies have investigated 
these associations specifically in black women.  
 
Methods: Black Women’s Health Study participants with an intact uterus 
(n=47,555) were followed for 18 years starting in 1995. Data on exogenous 
hormone use and covariates were obtained on the baseline questionnaire and 
updated biennially. Diagnosis of endometrial cancer was self-reported and, 
where possible, was confirmed using medical records or cancer registry data. We 
estimated incidence rate ratios (IRR) and 95% confidence intervals (CI) using 
Cox regression models.  
 
Results: We observed 300 endometrial cancer cases over 689,501 person-years 
of follow-up. The multivariable-adjusted IRR for ≥10 years’ duration of OC use, 
compared with never use, was 0.45 (95% CI: 0.27, 0.74). Compared with never 
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users of any FMH, risk appeared to be higher in current users of estrogen-only 
FMH (IRR=3.66, 95% CI: 1.64, 8.18), and estrogen plus progestin FMH 
(IRR=1.55, 95% CI: 0.78, 3.11), but lower in former users of both types 
(estrogen-only IRR=0.87, 95% CI: 0.44, 1.71; estrogen plus progestin IRR=0.63, 
95% CI: 0.36, 1.09). 
 
Conclusions: Our results indicate that associations of endometrial cancer with 
exogenous hormone use among black women are comparable to those reported 
among white women.  
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4.2 Introduction 
 Most epidemiologic studies have found an inverse association between 
the use of oral contraceptives (OCs) and endometrial 
cancer,1,3,11,14,16,18,23,24,31,34,35 although one reported a positive association.33 
Stronger inverse associations have been reported for longer durations of 
use,3,11,14,16,18,23,35 which may continue at least 20 years after cessation.23,31 Use 
of estrogen-only female menopausal hormones (FMH) has been associated with 
an increased risk of endometrial cancer,2,5,13,15,20,26,30,32 with relative risks ranging 
from 2.0 to 10.0 for long-term use (generally ≥5 or ≥10 years).20,26,30,32 In an effort 
to reduce endometrial cancer risk, progestins were added to FMH formulations. 
The earliest formulations of these drugs tended to administer progestins 
sequentially for one to three weeks every month. Studies of sequential FMHs 
have been inconsistent, with reports of increased risk13,17,20,26,27,32 or no 
association with endometrial cancer.22,30 Most studies have found that FMH 
formulations in which progestins are taken continuously decrease 
risk3,5,9,13,17,25,27,30,32 but others have found positive associations20 or no 
association.22 
 We found only two studies (524 total black cases), a pooled analysis of 11 
U.S. studies (4 case-control and 7 cohort)11 and a case control study from South 
Africa,34  that examined the association of OCs and endometrial cancer among 
black women. The results of both studies were comparable to findings among 
white women. To our knowledge, no studies of the association of endometrial 
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cancer with FMH have reported race-stratified estimates. Obesity is a potential 
modifier of the associations of endometrial cancer with FMH.5,13,15,30 These 
associations may differ in black compared with white women due to black 
women’s higher prevalence of obesity.6 In order to contribute to the body of 
evidence regarding use of exogenous hormones and risk of endometrial cancer 
in black women, we evaluated these relationships in the Black Women’s Health 
Study. We also analyzed type I and type II/III endometrial cancers separately to 
look for evidence of etiologic heterogeneity. 
 
4.3 Methods 
4.3.1 Data Source 
 The Black Women’s Health Study (BWHS) is an ongoing prospective 
cohort of 59,001 self-identified black women.28 Participants were recruited from 
the subscription list of Essence magazine, black professional organizations, and 
friends and relatives of study participants. In 1995, participants aged 21–69 were 
mailed questionnaires to gather information about demographic factors, 
reproductive history, health history, smoking, alcohol consumption, 
anthropometric measurements, and other factors. Outcome, exposure, and 
covariate data are updated on biennial questionnaires. Through 2013, complete 
follow-up data are available for approximately 87% of potential person time. The 
study methods were approved by the institutional review board of Boston 
University, Boston, Massachusetts. 
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 Women reporting a history of uterine cancer (n=258), cervical cancer 
(n=82), or hysterectomy (n=10,659), or who only returned the baseline 
questionnaire (n=447) were excluded at baseline. The remaining 47,555 women 
were followed for incident endometrial cancer from 1995 through 2013.  
 
4.3.2 Outcome 
Potential incident endometrial cancers were ascertained via self-reported 
new diagnoses of “uterine cancer” on follow-up questionnaires from 1997 through 
2013. In 1995 and 2011, women were not asked specifically about uterine cancer 
but could report diagnosis as “other serious illness.” Cases were also identified 
through state cancer registries, representing 24 states where 95% of participants 
lived, and death certificate data from the National Death Index (NDI). Of a total of 
367 potential cases, 18 reported that they had a condition other than uterine 
cancer when contacted for permission to release medical records. We obtained 
medical records, cancer registry data, or death certificate data for 249 of the 
remaining 349 cases (71%). Two hundred thirty one out of 249 (93%) were 
confirmed as either endometrial cancer (n=213) or uterine sarcoma (n=18). Due 
to the high confirmation rate, we included the remaining unverified cases in the 
analysis. After the exclusion of uterine sarcomas, there were a total of 213 
confirmed and 87 unverified cases, for a total of 300 available for study. 
International Classification of Diseases for Oncology (ICD-O) codes were 
available to allow 182 of the 213 (85%) confirmed case to be classified under one 
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of three major histological types; 131 (72%) were classified as type I, 30 (16%) 
as type II, and 21 (12%) as type III (Appendix 2, Table 16).36 
 
4.3.3 Exposures  
 At baseline, women were asked: “…if you have ever used birth control 
pills, for each age at which you used birth control pills, mark how long you used 
them (mark one circle for each age).” Choices included “less than 6 months”, “6–
9 months” or “10 or more months” for duration of use during each age from “13 or 
less” to “45 or more” in one-year increments. On subsequent questionnaires, 
they indicated if they had used OCs since the last questionnaire, as well as the 
duration of use during that period (options “less than 6 months”, “6–11 months”, 
“12–17 months”, “18 months or more” in 1997, 1999, and 2001; they were asked 
to fill in the exact number of months in 2003, 2005, 2007, 2009, 2011, and 2013).  
In 1995, women reported whether or not they had “ever used replacement 
female hormones (like estrogen) for menopause (includes pill, injections, or 
patches)”, when they last took them (“still taking them”, “less than 1 year ago”, 1–
2 years ago”, or “3 or more years ago”), and how many years they took them 
(“less than 1 year”, “1 year”, “2 years”, “3–4 years”, “5–6 years”, “7–9 years”, “10–
14 years”, or “15 or more years”). In addition, we asked which type was used 
most recently (“Premarin or other estrogen pills alone”, “progesterone (Provera, 
etc.) pills alone”, “estrogen and progesterone together”, “patch estrogen alone”, 
“patch estrogen and progesterone”, or “estrogen vaginal cream”), and the name 
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of the medication. Women who reported progestin use were asked “what was 
your pattern of use?” (“used continuously (every day)”, “used 2–3 weeks each 
month”, “used less than 2 weeks each month”, “other pattern of use”). On 
subsequent questionnaires, we asked whether they had used “estrogen 
replacement therapy (“pills, injections, or patches”) since the last questionnaire, 
the duration of use during that period (provided options “less than 6 months”, “6–
11 months”, “12–17 months”, “18 months or more” in 1997, 1999, and 2001; 
asked to fill in how many months in 2003, 2005, 2007, 2009, 2011, and 2013), 
the type of hormone used most recently (“Premarin or other estrogen pills alone”, 
“Progesterone (Provera etc.) pills alone”, “estrogen and progesterone pills”, 
“patch estrogen alone”, “patch estrogen and progesterone”, or “estrogen vaginal 
cream” in 1997, 1999, 2001, and 2003; additionally “birth control pill (for 
menopause)” in 2003), and the name of the hormone used most recently (all 
questionnaires). Data on pattern of progestin use in estrogen plus progestin FMH 
users were not collected after the baseline questionnaire. Use of estrogen 
vaginal cream was not considered exposure to estrogen-only FMH. 
 
4.3.4 Covariates 
Data on age at menarche, height, and weight at age 18 was collected via 
the baseline questionnaire in 1995. Women reported current weight, physician-
diagnosed diabetes, age at first birth, parity, gynecologic surgeries 
(hysterectomy, bilateral oophorectomy, unilateral oophorectomy), and 
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menopausal status at baseline and updated on follow-up questionnaires. Body 
mass index (BMI) at age 18 and current BMI were calculated as weight 
(kg)/height (m)2. Menopause was defined as the absence of menstrual periods 
within the last 12 months. Current users of FMH who were unsure of their 
menopausal status were classified as postmenopausal if aged ≥57 years and 
premenopausal if aged <43 years. Data on vigorous exercise (hours/week) were 
collected from 1995–2001 and 2007–2011. Marital status was reported in 1995, 
1997, 1999 and 2003. Participants reported their education level at baseline, 
household income in 2003, and parental and partner/spousal education in 2009.  
 
4.3.5 Data Analysis 
 We followed participants from baseline until the diagnosis of endometrial 
cancer or one of the following censoring events: diagnosis of non-epithelial 
uterine cancer (n=52), hysterectomy (n=7,564), loss-to-follow-up (n=13,108), or 
the end of follow-up (2013), whichever came first. For all categories of exposure, 
we calculated crude incidence rates and estimated incidence rate ratios (IRR) 
compared with the reference category. We used Cox proportional hazards 
regression models12 stratified jointly by age in 1 year increments and 
questionnaire cycle to calculate adjusted IRRs and 95% confidence intervals 
(CI). Due to the lack of time-varying data on pattern of estrogen plus progestin 
FMH use, this variable was analyzed using only baseline data with age as the 
time scale. We updated time-varying covariates using the Andersen-Gill data 
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structure4 for all other exposures. Missing values were imputed by carrying 
forward the last observation. We conducted tests for linear trend by modeling the 
median values of each exposure category as a continuous variable. Departures 
from proportional hazards were assessed by comparing models with and without 
interaction terms between exposures and each of the time scales (age and 
questionnaire cycle) using the likelihood ratio test.  
 Time-varying variables were defined similarly for OCs and FMH. Ever use 
was defined as a report on the current or any prior questionnaire. An ever user 
was classified as a current user if she reported any use since the last 
questionnaire, otherwise she was classified as a former user. Duration of use 
was determined at baseline and updated whenever a woman reported use since 
the prior questionnaire. Recency of use was determined at baseline. If an ever 
user reported use since the prior questionnaire, recency was set to 0, otherwise 
2 years were added to the value from the prior questionnaire cycle. Where 
women were asked to select from a list of pre-defined categories for recency or 
duration, the midpoint of the category was selected as the value used in 
calculating the variable. For the highest category (e.g. “18 months or more”), the 
lowest value (e.g., 18 months) of the category was used. When questionnaires 
asked participants to list the number of months of use since the prior 
questionnaire, that number of months was added unless it was higher than 24, in 
which case 24 months was added to the total. Months of use were converted to 
years of use by dividing by 12. 
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For OCs, duration of use was categorized as (0, 1–4, 5–9, and ≥10 years). 
Recency was categorized as (never user, current user, 1–9, 10–19, 20–29, ≥30 
years). We also cross-tabulated recency and duration of use in categories, 
comparing never users to each combination of duration (1–4, ≥5 years) and 
recency (1–9, 10–19, ≥20 years). For FMH, duration was categorized as (0, 1–4, 
≥5 years) and recency as (never user, current user, 1–9, ≥10 years).  
 To control for confounding, we adjusted for a set of known or suspected 
risk factors for endometrial cancer selected a priori. These covariates included 
age at menarche (<11, 11, 12–13, ≥14 years), parity (parous, nulliparous), 
menopausal status (premenopausal, postmenopausal), smoking status (never, 
former, current), vigorous physical activity (0, 1–4, ≥5 hours/week), and BMI 
(<25, 25–29, 30–34, 35–39, ≥40 kg/m2). Models were mutually adjusted for OC 
use (never, former, current) and use of estrogen-only and estrogen plus 
progestin female hormones (never, former, current). We examined potential 
confounding by BMI at age 18, history of infertility, income and marital status. 
Inclusion of these variables did not change the effect estimates appreciably 
(<10%), and we omitted them from the final models. 
 Young women are both at low risk for endometrial cancer and are unlikely 
to use FMH for menopause. We therefore restricted the analysis of FMH to 
women who were a) 40 years or older, b) had known menopausal status, and c) 
did not report current use of OCs. Each type of FMH (estrogen-only, estrogen 
plus progestin, and progestin-only) was analyzed separately, and restricted to 
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person-years contributed by women who used only the specified type compared 
to women who did not report any FMH use (estrogen-only, estrogen plus 
progestin, progestin-only, or unknown type). Few women (2,159 women, 17,099 
person-years, 3 cases) switched from one FMH type to another, so we did not 
perform separate analyses in these women. No other combinations of use were 
observed in the dataset. 
Separate analyses were performed to investigate the association of type I 
and type II/III endometrial cancers with exogenous hormone use, censoring all 
other incident cases. In order to evaluate the impact of the inclusion of unverified 
cases on our results, we analyzed the data using only confirmed cases, 
censoring all other incident cases,  
All analyses were conducted using SAS software, version 9.4 (SAS 
Institute, Inc., Cary, North Carolina). 
 
4.4 Results 
We observed 300 endometrial cancer cases during 689,501 person-years 
of follow up. The mean age of participants at baseline was 36.6 years and 9.8% 
were menopausal. (Table 10). The mean BMI was 27.7 kg/m2. Mean length of 
follow-up was 14.5 years. OCs had been used by 85.5%. The percentages of 
women using FMHs at baseline were 1.4%, 3.5% and 1.4% for estrogen-only, 
estrogen plus progestin, and progestin only, respectively. 
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 After adjustment for potential confounders, the IRR comparing ever with 
never use of OCs was 0.86 (95% CI: 0.63, 1.18) (Table 11). The IRRs for former 
and current use compared with never use were 0.87 (95% CI: 0.64, 1.20) and 
0.69 (95% CI: 0.40, 1.20), respectively. Our data were consistent with a gradual 
diminishing of the protective association between OC use and endometrial 
cancer with increasing time since last use. The IRRs for 1–9, 10–19, 20–29, and 
≥30 years since last use compared with never use were 0.69 (95% CI: 0.44 
1.08), 0.85 (95% CI: 0.54, 1.32), 0.98 (95% CI: 0.66, 1.45), and 0.89 (95% CI: 
0.62, 1.28), respectively (Ptrend=0.43). There was an inverse relation between the 
duration of OC use and endometrial cancer risk, with the IRRs for 1–4, 5–9 and 
≥10 years of use vs. never use 0.98 (95% CI: 0.71, 1.35), 0.74 (95% CI: 0.48, 
1.13) and 0.45 (95% CI: 0.27, 0.74), respectively (Ptrend=0.0002). The inverse 
association between OC use and endometrial cancer risk among women who 
used OCs ≥5 years compared with never users changed little for up to 20 years 
since last use. The IRRs for <10, 10–19 and ≥20 years since last use in such 
women were 0.45 (95% CI: 0.26, 0.76), 0.51 (95% CI: 0.26, 0.99), and 0.80 (95% 
CI: 0.51, 1.25), respectively (Ptrend=0.49). There was little evidence for an 
association among women who used OCs for <5 years in any recency category.  
 Risk was higher among women who used estrogen-only FMH compared 
with women who never used any FMH (Table 12). The IRR for current use vs. 
never use was 3.66 (95% CI: 1.64, 8.18). Risk was higher among women with a 
duration of use ≥5 years (IRR=1.88, 95% CI: 0.59, 6.04) than among women 
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whose duration of use was 1–4 years (IRR=1.24, 95% CI: 0.69, 2.20,), although 
these estimates were based on only 3 and 13 exposed cases, respectively.  
 Ever users of estrogen plus progestin FMH formulations had slightly lower 
risk than never users of any FMH (IRR=0.82, 95% CI: 0.53, 1.28) (Table 12). 
However, while risk was lower among former users (IRR=0.63, 95% CI: 0.36, 
1.09), it was higher among current users (IRR=1.55, 95% CI: 0.78, 3.11). In 
analyses of baseline data on the pattern of progestin use, risk was higher among 
users of sequential estrogen plus progestin FMH taking progestins <2 
weeks/month (IRR=1.42, 95% CI: 0.76, 2.65) and lower among continuous users 
of progestin (IRR=0.83, 95% CI: 0.40, 1.73) compared with women who never 
used any FMH (Appendix 3 Table 21). 
Women who used progestin-only FMH were at increased risk of 
endometrial cancer compared with never users of any FMH (Table 12). The IRR 
comparing ever use with never use of any FMH was 1.51 (95% CI: 0.73, 3.08, 
based on 8 cases).  
We observed little convincing evidence of differences in the associations 
of exogenous hormones with endometrial cancer subtypes (Appendix 3 Table 
22). When analyses were restricted to confirmed endometrial cancer cases, the 
IRR for a duration of <5 years of OC use and last use within the last 10 
(IRR=0.51, 95% CI: 0.27, 0.97) years was similar to a duration of ≥ 5 years with 
the same recency (IRR=0.52, 95% CI: 0.28, 0.96) (Appendix 3, Table 23). In 
contrast, the IRR for <5 years of OC use and last use within the last 10 years 
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(IRR=0.91, 95% CI: 0.58, 1.45) was closer to the null than for ≥5 years of OC use 
and last use within the last 10 years (IRR=0.45, 95% CI: 0.26, 0.76) in the main 
analysis. The association with progestin-only FMH use was also weakened. 
Associations with other variables were comparable to the main analysis.  
 
4.5 Discussion 
 In this prospective cohort study of U.S. black women, long term OC use 
was associated with reduced endometrial cancer risk. Current use of estrogen-
only FMH strongly increased risk, while there was no appreciable association of 
risk with former use. Our results for estrogen plus progestin FMH suggested an 
increased risk among current users but a decreased risk among former users, 
although we had little data on pattern of progestin use and numbers of users 
were small.  
 According to the unopposed estrogen hypothesis,19 endometrial cancer 
risk is primarily determined by the mitotic rate of endometrial cells, which is 
increased by estrogens in the absence of progestogens. Therefore the use of 
exogenous estrogens and progestins is likely to influence endometrial cancer 
risk. 
 Virtually every study of the use of OCs and endometrial cancer risk has 
found an inverse association.1,3,11,14,16,18,23,24,31,34,35 A recent meta-analysis of 36 
studies with 27,276 endometrial cancer cases found a summary odds ratio (OR) 
of 0.69 (95% CI: 0.66, 0.73) for the association of ever vs. never OC use.10 This 
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was lower, although not incompatible, with our result of 0.86 (95% CI: 0.63, 
1.18). Likewise, our finding of reduced risk with increasing lifetime duration of use 
was comparable to the meta-analysis of OCs with RRs of 0.81 (95% CI: 0.76, 
0.86), 0.64 (95% CI: 0.59, 0.69), 0.52 (95% CI: 0.47, 0.58) and 0.32 (95% CI: 
0.28, 0.38) for 1–4, 5–9, 10–14, and ≥15 years of use.10 It is therefore likely, that 
our higher estimate of risk among ever users was attributable, in part, to the 
relatively low proportion of long-duration users in our study.  
 The majority of studies have found that women who used estrogen-only 
FMH have a higher risk of endometrial cancer compared with never users of 
FMH.2,5,13,15,20,26,30,32 In our study, current users had nearly 3.7 times the risk of 
never FMH users, although former users were not at increased risk. Most 
previous studies have found increasing risk with increasing duration of 
use,13,20,26,30,32 although one small study did not.15 Prior studies have reported 
relative risks ranging from 2 to 10 among long term users.20,26,30,32  Our estimates 
were consistent with increased risk with long term use, although they were based 
on few cases and imprecisely estimated.  
 Endometrial cancer incidence was elevated among current users of 
combined estrogen-progestin FMH, but lower among former users compared 
with never users. The association of estrogen plus progestin FMH is complicated 
by different formulations and patterns of progestin use in these drugs. Sequential 
formulations, where estrogens are taken alone for a portion of a given month and 
progestins are added for the remainder of the month, may increase 
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risk,13,17,20,26,27,32 although some studies have observed no association.22,30 In 
contrast, most3,5,9,13,17,25,27,30,32 but not all20,22,26 studies have found that 
continuous combined estrogen plus progestin FMH decrease risk. Our analysis 
of the baseline data on patterns of progestin use in FMH was consistent with this, 
although our estimates were imprecise. In our time-varying analysis, risk was 
lower among former users of estrogen plus progestin FMH compared with never 
users of FMH, but higher among current users. It is difficult to compare our 
results with previous studies without knowing which types (sequential vs. 
continuous) were being used by our current and former users. 
 Our data suggested that women who used progestin-only FMH were at 
increased risk of endometrial cancer. Progestin-only FMH are a standard 
treatment for endometrial hyperplasia.8 Lacey et al. found that, accounting for 
treatment, women seeking biopsy and diagnosed with any type of endometrial 
hyperplasia had four times the risk of endometrial cancer compared with those 
diagnosed with disordered proliferative endometrium, with risk ratios ranging 
from 2.0 to 14.2 depending on presence of atypia.21 Women with atypical 
hyperplasia remained at substantially increased risk after 5 years. Although we 
lack data on this condition, our results are consistent with progestin-only FMH 
use being a marker for endometrial hyperplasia. Thus, the apparent increase in 
endometrial cancer risk may be due to confounding by indication. 
 We did not find compelling evidence for differences in associations of 
histologic subtypes of endometrial cancer with exogenous hormone use. The 
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small numbers of type II and III cancers in our study limited our power to detect 
any potential differences in these associations. Recent studies of risk factors for 
histologic subtypes have found little evidence of differences in associations with 
OC use between type I and II tumors29 or FMH with type I, II, or III cancers.7  
 Our study had a number of strengths. We analyzed data from a large 
prospective cohort study of self-identified black women. To the best of our 
knowledge, this is the first report of the association between FMH and 
endometrial cancer specifically in black women. We had data on a large number 
of potential confounders, including anthropometric and reproductive factors.  
 There were several notable limitations. Foremost among them were the 
low prevalence of FMH use among women with an intact uterus and the high 
prevalence of short duration OC use, which resulted in limited power. Our OC 
analysis did not take into account changes that have occurred in these 
formulations over time. Hormone dosages have decreased over time, and a 
sequential formula that was associated with increased risk of endometrial cancer 
was used until 1979. However, prior studies have not found a large influence of 
dose on the overall effect of OC use and endometrial cancer.24,35 Of greater 
concern is the limited data on the pattern of estrogen plus progestin FMH that 
were used. This is likely to have a large influence on the overall results, as the 
different patterns of progestin use may differ in their associations with 
endometrial cancer.  
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Our data are based on self-report. Thus, we would expect some degree of 
misclassification of exposure. As our data were collected prospectively, 
misclassification was most likely non-differential. In the case of dichotomous 
exposures and in the extreme categories of polytomous categorical variables, the 
expected direction of bias is towards the null, while the direction of bias for 
intermediate categories of such variables is not predictable in general. We also 
included unconfirmed cases in our analysis, which may have resulted in 
misclassification of outcome. Analyzing only confirmed cases did not 
substantially alter the results. The inclusion of conditions whose associations with 
the exposures in this study differ from those of endometrial cancer in the case 
group could result in a differential bias whose direction would depend on the 
nature of those differences. However, estimated associations were generally 
similar to the results presented when we restricted analysis to confirmed cases. 
BWHS participants may differ from the U.S. black population as a whole in ways 
that could influence our results. This could limit generalizability of our findings. 
We found that associations between use of exogenous hormones and 
endometrial cancer in black women appeared to be generally similar to what has 
been reported previously in white women. However, due to the low prevalence of 
FMH use and lack of data on the pattern of progestin use in estrogen plus 
progestin FMH users in our study, our finding on the associations between 
endometrial cancer and FMH use in black women require confirmation in other 
studies.  
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Table 10. Age-Standardized Baseline Characteristicsa of 47,555 Participants in 
the Black Women’s Health Study, 1995 
Age in 1995, years, mean (SD) 36.6 (9.8) 
Education, years, mean (SD) 14.8 (1.8) 
Marital status  
     Single, % 38.8 
     Married/living together, % 38.4 
     Separated/Divorced/Widowed, % 21.8 
Age at menarche, years, mean (SD) 12.3 (1.6) 
History of infertility, % 8.9 
Parous, % 60.7 
Postmenopausal, % 9.8 
Body mass index, kg/m2, mean (SD) 27.7 (6.7) 
Vigorous physical activity, hours/week  
     1–4, % 51.4 
     ≥5, % 13.7 
Ever use of oral contraceptives, % 85.5 
Ever use of estrogen-only FMH, % 1.4 
Ever use of estrogen plus progestin FMH, % 3.5 
Ever use of progestin-only FMH, % 1.4 
Abbreviations: FMH, female menopausal hormones; SD, standard deviation. 
a Values are standardized to the age distribution of the study population. 
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Table 11. Association of Endometrial Cancer With Oral Contraceptive Use, 1995–2013 
     Age Adjusteda  Multivariable Adjustedb 
Exposure Cases Person-Years Ratec  IRR 95% CI  IRR 95% CI 
Oral contraceptive use          
     Never 57 79,594 71.6  1.00 Referent  1.00 Referent 
     Ever 243 609,906 39.8  0.72 0.53, 0.98  0.86 0.63, 1.18 
          Former 221 489,406 45.2  0.74 0.54, 1.00  0.87 0.64, 1.20 
               1–9 yearsd 40 174,341 22.9  0.52 0.34, 0.80  0.69 0.44, 1.08 
               10–19 years 38 134,455 28.3  0.72 0.46, 1.13  0.85 0.54, 1.32 
               20–29 years 58 105,042 55.2  0.85 0.58, 1.26  0.98 0.66, 1.45 
               ≥30 years 77 62,163 123.9  0.79 0.55, 1.14  0.89 0.62, 1.28 
          Current 22 120,500 18.3  0.61 0.36, 1.03  0.69 0.40, 1.20 
          
     Duration, years          
          1–4 165 325,167 50.7  0.84 0.61, 1.15  0.98 0.71, 1.35 
          5–9 42 142,583 29.5  0.59 0.39, 0.90  0.74 0.48, 1.13 
          ≥10 24 122,339 19.6  0.37 0.22, 0.60  0.45 0.27, 0.74 
          Ptrend      <0.0001   0.0002 
          
     Recency, years x  
        duration, years 
         
          <10, <5 36 118,125 30.5  0.74 0.48, 1.14  0.91 0.58, 1.45 
          <10, ≥5 22 168,133 13.1  0.34 0.20, 0.58  0.45 0.26, 0.76 
          10–19, <5 27 76,367 35.4  0.96 0.59, 1.58  1.09 0.66, 1.80 
          10–19, ≥5 11 58,087 18.9  0.41 0.21, 0.80  0.51 0.26, 0.99 
          ≥20, <5 102 129,808 78.6  0.85 0.60, 1.18  0.95 0.68, 1.34 
          ≥20, ≥5 33 37,397 88.2  0.69 0.45, 1.08  0.80 0.51, 1.25 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio. 
a Stratified jointly by age and study period. 
b Stratified by age and study period and adjusted for age at menarche, parity, menopausal status, estrogen-only female menopausal 
hormone use, estrogen plus progestin female menopausal hormone use, smoking status, body mass index, and vigorous physical 
activity. 
c Crude incidence rate per 100,000 person-years. 
d Years since last use; Ptrend=0.03 (age- and period adjusted); Ptrend=0.49 (multivariable adjusted). 
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Table 12. Association of Endometrial Cancer With Female Menopausal Hormone Use, 1995–2013a 
     Age Adjustedb  Multivariable Adjustedc 
Exposure Cases Person-Years Rated  IRR 95% CI  IRR 95% CI 
Estrogen-only FMH  
   use 
         
     Nevere 155 277,471 55.9  1.00 Referent  1.00 Referent 
     Ever 16 12,130 131.9  1.28 0.76, 2.17  1.30 0.77, 2.20 
          Former 9 8,882 101.3  0.86 0.44, 1.70  0.87 0.44, 1.71 
               1–9 yearsf 5 6,230 80.3  0.71 0.29, 1.73  0.73 0.30, 1.78 
               ≥10 years 4 2,637 151.7  1.19 0.43, 3.26  1.15 0.42, 3.17 
          Current 7 3,248 215.5  3.45 1.56, 7.65  3.66 1.64, 8.18 
          Duration, years          
               1–4 13 10,668 121.9  1.22 0.68, 2.16  1.24 0.69, 2.20 
               ≥5 3 1,271 236.0  1.85 0.58, 5.89  1.88 0.59, 6.04 
          
Estrogen plus  
   progestin FMH use   
       
  
     Nevere 155 277,471 55.9  1.00 Referent  1.00 Referent 
     Ever 25 28,602 87.4  0.71 0.46, 1.11  0.82 0.53, 1.28 
          Former 15 17,790 84.3  0.55 0.32, 0.96  0.63 0.36, 1.09 
               1–9 yearsf 9 13,586 66.2  0.46 0.23, 0.92  0.53 0.27, 1.06 
               ≥10 years 6 4,180 143.5  0.79 0.34, 1.83  0.86 0.37, 2.01 
          Current 10 10,812 92.5  1.29 0.65, 2.56  1.55 0.78, 3.11 
          Duration, years          
               1–4 16 20,356 78.6  0.71 0.42, 1.20  0.79 0.47, 1.34 
               ≥5 9 7,304 123.2  0.81 0.41, 1.61  0.98 0.49, 1.97 
          
Progestin-only FMH  
   use 
       
  
     Nevere 155 277,471 55.9  1.00 Referent  1.00 Referent 
     Ever 8 7,366 108.6  1.74 0.85, 3.56  1.51 0.73, 3.08 
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Table 12. continued 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio; FMH, female menopausal hormones. 
a Analysis restricted to women ≥40 years of age, not taking oral contraceptives, with known menopause status, and not reporting use of 
multiple FMH types. 
b Stratified jointly by age and study period. 
c Stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, smoking 
status, body mass index, and vigorous physical activity. 
d Crude incidence rate per 100,000 person-years. 
e Never reported use of any type of FMH. 
f Years since last use. 
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5 Conclusions 
 A substantial body of research on endometrial cancer etiology, conducted 
primarily among white women, has identified several metabolic, reproductive, 
and hormonal risk factors, including obesity,4,7,9,11,15,20,24,38,51,53,58,61 ages at 
menarche17,28,30,39,47,59,60 and menopause,17,28,30,39,47,59,60 parity,5,8,17,28,33,39,42,59 
oral contraceptive use,4,13,17,25,29,35,37,52,56,57 and use of female menopausal 
hormones.3,6,12,16,18,31,43,44,50,54 The incidence of aggressive endometrial cancer 
subtypes,27,49 and perhaps overall incidence,27 is higher among black women and 
is increasing. However, the relative paucity of data on the associations of 
endometrial cancer with established risk factors in black women have left open 
the possibility that differences in these associations may partially explain the 
disparity. The principal goal of this dissertation was to explore such potential 
differences in a large prospective cohort of U.S. black women. 
 In the first study, total obesity, as measured by BMI, was strongly related 
to endometrial cancer risk. Measures of abdominal obesity were also positively 
associated, but these associations were greatly diminished after control for BMI. 
Risk was higher among women with a high BMI at age 18, who had gained 
excess weight since age 18, and who had been diagnosed with diabetes. 
Hypertension and hypercholesterolemia had little association with risk. Our 
findings regarding early-adult9,10,15,24 and current4,7,9,11,20,24,38,45,47,51,53,55,58,60,61 
total obesity, weight gain,4,9,10,24 and diabetes13,19,36 were comparable with those 
in the previous literature. Most studies reporting positive associations of 
 97 
endometrial cancer with measures of central and peripheral adiposity4,9,14,15,20,45 
did not control for BMI, which may partly explain the lack of associations in the 
BWHS. Prior evidence for associations with hypercholesterolemia14,21,48 and 
hypertension14,21,40 is not consistent, and these factors were not associated with 
endometrial cancer in our study. 
 Study 2 examined the associations of endometrial cancer with 
reproductive factors. Early age at menarche, a greater number of lifetime 
menstrual cycles, diagnosis of PCOS, and history of infertility were associated 
with increased risk, while parity and late age at first birth were associated with 
decreased risk. A greater number of births and history of breastfeeding were not 
associated with endometrial cancer among parous women. In stratified analyses, 
late age at first birth was inversely associated with risk among premenopausal 
women, and long-duration breastfeeding was associated with increased risk 
among obese women.  
The prior literature supports positive associations of endometrial cancer 
with early age at menarche17,28,30,39,47,59,60 and a greater number of ovulatory 
cycles,39,46,59 and an inverse association with parity.5,8,17,28,33,39,42,59 Inverse 
associations have also been reported with a greater number of births,8,17,23,30,33,42 
later age at first birth,8,23,30,41,59 later age at last birth,28,30,33,34 and 
breastfeeding.46,59 Differences between our study, which only supported the 
association with age at first birth, may be due to collinearity between many of 
these exposures and differences in covariates included in models. Modification of 
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the associations of endometrial cancer with late age at menarche by menopausal 
status and breastfeeding by obesity require confirmation in other studies. 
The results of study 3 support the previously observed inverse association 
of endometrial cancer with oral contraceptive use,1,2,5,13,17,25,29,35,37,52,57 
particularly in long-duration users.5,17,25,29,35,56,57 The prevalence of FMH use was 
low in our study. Risk was higher among users of estrogen-only FMH, as has 
been reported elsewhere.3,6,16,18,31,43,50,54 Unlike most of these studies, however, 
higher risk was mainly seen in current users. Risk was also higher among current 
users of estrogen plus progestin FMH, but lower in former users. In previous 
investigations, most studies found higher risk in sequential estrogen plus 
progestin FMH 16,26,31,32,43,50,54 but lower risk in users of continuous combined 
formulations.16,22,31,32,43,44,50,54 It is difficult to compare our results to past studies 
because we only had data on formulation of estrogen plus progestin FMH at 
baseline.  
In conclusion, we found little evidence that associations of endometrial 
cancer with anthropometric, metabolic, reproductive, or exogenous hormones in 
black women differ substantially from what has been reported in studies that 
have mainly included white women. Therefore, such differences appear to be an 
unlikely explanation for differences in endometrial cancer incidence between 
black and white women. Although this conclusion requires further supporting 
evidence, the prevalence of known risk factors and/or novel risk factors may 
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prove better avenues for investigating the origin of endometrial cancer disparities 
among black and white women. 
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 6 Appendices 
6.1 Appendix 1: Body Size, Metabolic Factors, and Risk of Endometrial 
Cancer in Black Women 
 
6.1.1 Associations of anthropometric and metabolic factors with 
endometrial cancer, restricted to confirmed cases 
 Associations were strengthened slightly when we analyzed confirmed 
cases, censoring those that were not validated. This was true of anthropometric 
exposures (Table 12), obesity and change in weight (Table 13), and metabolic 
exposures (Table 14). 
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Table 13. Associations Between Measures of Body Size and Endometrial Cancer Risk in the Black Women’s Health Study, Confirmed 
Cases Only 
    Age Adjusteda  Multivariable Adjustedb 
Variable Cases Person-Years 
Incidence 
Ratec 
IRR 95% CI 
 
IRR 95% CI 
Body mass indexd,e         
     <25 22 206,692 10.6 1.00 Referent  1.00 Referent 
     25–29 44 210,657 20.9 1.27 0.77, 2.11  1.27 0.75, 2.14 
     ≥30 125 241,098 51.8 3.12 2.00, 4.87  2.61 1.56, 4.36 
          30–34 47 126,267 37.2 2.18 1.31, 3.62  2.18 1.24, 3.82 
          35–39 34 62,847 54.1 3.41 1.99, 5.85  3.14 1.71, 5.79 
          ≥40 44 51,984 84.6 6.24 3.73, 10.45  5.15 2.80, 9.50 
          Ptrend     <0.0001   <0.0001 
         
Quartile of weight-to- 
   height ratiod,f 
     
 
  
     1 (<39.7) 40 309,836 12.9 1.00 Referent  1.00 Referent 
     2 (39.7–45.7) 60 200,917 29.9 1.69 1.13, 2.52  1.68 1.09, 2.59 
     3 (45.8–53.7) 40 87,552 45.7 2.72 1.75, 4.23  2.46 1.49, 4.07 
     4 (≥53.8) 51 58,948 86.5 6.21 4.09, 9.43  5.03 3.02, 8.36 
     Ptrend     <0.0001   <0.0001 
         
Waist circumference,  
   cmg 
     
 
  
     <80 39 242,878 16.1 1.00 Referent  1.00 Referent 
     80–87 26 111,449 23.3 0.99 0.60, 1.64  0.80 0.48, 1.94 
     ≥88 98 164,160 59.7 2.19 1.50, 3.19  1.14 0.73, 1.78 
     Ptrend     <0.0001   0.60 
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Table 13. continued 
    Age Adjusteda  Multivariable Adjustedb 
Variable Cases Person-Years 
Incidence 
Ratec 
IRR 95% CI 
 
IRR 95% CI 
Waist-to-hip ratiog         
     <0.80 91 312,852 29.1 1.00 Referent  1.00 Referent 
     0.80-0.84 30 918,818 32.7 0.98 0.65, 1.48  0.94 0.62, 1.42 
     ≥0.85 52 162,905 31.9 0.98 0.69, 1.38  0.88 0.62, 1.24 
     Ptrend     0.96   0.46 
         
Quartile of waist-to- 
   height ratiog 
     
 
  
     1 (<0.435) 28 166,930 16.8 1.00 Referent  1.00 Referent 
     2 (0.435–0.485) 47 216,709 21.7 0.81 0.50, 1.29  1.20 0.73, 1.95 
     3 (0.486–0.553) 61 104,050 58.6 1.76 1.12, 2.77  0.84 0.50, 1.40 
     4 (≥0.554) 26 29,321 88.7 2.56 1.49, 4.39  1.18 0.72, 1.95 
     Ptrend     <0.0001   0.70 
         
Quartile of waist-to- 
   height ratiog 
     
 
  
     1 (<0.435) 28 166,930 16.8 1.00 Referent  1.00 Referent 
     2 (0.435–0.485) 47 216,709 21.7 0.81 0.50, 1.29  1.16 0.79, 1.69 
     3 (0.486–0.553) 61 104,050 58.6 1.76 1.12, 2.77  0.99 0.71, 1.37 
     4 (≥0.554) 26 29,321 88.7 2.56 1.49, 4.39  1.01 0.73, 1.40 
     Ptrend     <0.0001   0.87 
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Table 13. continued 
Abbreviations: BMI, body mass index; CI, confidence interval; IRR, incidence rate ratio.  
a Stratified jointly by age and study period. 
b Stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, estrogen-only 
female menopausal hormone use, estrogen plus progestin female menopausal hormone use, smoking status, type 2 diabetes, 
hypertension, hypercholesterolemia, and vigorous physical activity. 
c Per 100,000 person-years. 
d Additionally adjusted for waist circumference. 
e Weight (kg)/height (m)2. 
f Weight (kg)/height (m). 
g Additionally adjusted for body mass index. 
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Table 14. Associations of Early Adulthood Obesity and Change in Weight Since Early Adulthood With 
Endometrial Cancer Risk, Black Women’s Health Study, 1995–2013, Confirmed Cases Only 
    Age Adjusteda  Multivariable Adjustedb 
Variable Cases Person-Years 
Incidence 
Ratec 
IRR 95% CI 
 
IRR 95% CI 
BMI age 18 yearsd,e         
     <18.5 29 111,511 26.0 0.80 0.53, 1.20  0.85 0.56, 1.28 
     18.5–24.9 117 430,511 27.2 1.00 Referent  1.00 Referent 
     25.0–29.9 19 68,541 27.7 1.42 0.87, 2.31  1.20 0.73, 1.96 
     ≥30.0 14 29,508 47.4 2.74 1.57, 4.79  1.97 1.11, 3.50 
     Ptrend     0.0001   0.01 
         
Quartile of weight-to-height  
   ratio at age 18d,f 
        
     1 (<31.6) 20 93,031 21.5 1.00 Referent  1.00 Referent 
     2 (31.6–34.1) 115 427,978 26.9 1.55 0.96, 2.49  1.46 0.91, 2.36 
     3 (34.2–38.2) 30 90,663 33.1 2.60 1.47, 4.59  2.13 1.20, 3.79 
     4 (≥38.3) 14 28,415 49.3 4.67 1.27, 4.84  3.17 1.57, 6.41 
     Ptrend     <0.0001   0.007 
         
Change in weight from age  
   18 years to present, kgg 
     
 
  
     <–5 3 12,033 24.9 2.34 0.60, 9.05  1.90 0.59, 7.44 
     -5–4 7 74,593 9.4 1.00 Referent  1.00 Referent 
     5–14 18 176,405 10.2 0.83 0.35, 2.00  0.85 0.35, 2.05 
     15–24 40 183,368 21.8 1.27 0.57, 2.85  1.14 0.47, 2.75 
     25–34 43 106,090 40.5 2.02 0.91, 4.49  1.50 0.60, 3.75 
     35–44 26 53,773 48.4 2.31 1.00, 5.34  1.33 0.50, 3.55 
     ≥45 49 48,540 100.9 4.96 2.24, 10.99  2.08 0.77, 5.63 
     Ptrend     <0.0001   0.32 
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Table 14. continued 
Abbreviations: BMI, body mass index; CI, confidence interval; IRR, incidence rate ratio. 
a Stratified jointly by age and study period. 
b Stratified by age and study period and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, estrogen-only 
female menopausal hormone use, estrogen plus progestin female menopausal hormone use, smoking status, type 2 diabetes, 
hypertension, hypercholesterolemia, and vigorous physical activity. 
c Per 100,000 person-years. 
d Additionally adjusted for waist circumference. 
e Weight(kg)/ height(m)2.. 
f Weight (kg/)/height (m). 
g Additionally adjusted for body mass index. 
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Table 15. Associations of Type 2 Diabetes, Hypertension, and Hypercholesterolemia With Endometrial Cancer Risk in the Black 
Women’s Health Study, 1995–2013, Confirmed Cases Only 
    Age Adjusteda  Multivariable Adjustedb 
Variable Cases Person-Years 
Incidence 
Ratec 
IRR 95% CI 
 
IRR 95% CI 
Type 2 diabetesd         
     Never 151 618,118 24.4 1.00 Referent  1.00 Referent 
     Ever 43 47,745 90.1 1.46 1.03, 2.07  1.14 0.79, 1.64 
Hypertensione         
     Never 79 477,167 16.6 1.00 Referent  1.00 Referent 
     Ever 115 188,695 60.9 1.37 1.01, 1.85  1.09 0.79, 1.50 
Hypercholesterolemiaf         
     Never 122 476,611 25.6 1.00 Referent  1.00 Referent 
     Ever 72 189,251 38.0 0.60 0.45, 0.82  0.56 0.41, 0.76 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio. 
a Stratified jointly by age and study period. 
b Stratified by age and study period, and adjusted for age at menarche, parity, menopausal status, oral contraceptive use, estrogen-only 
female menopausal hormone use, estrogen plus progestin female menopausal hormone use, smoking status, type 2 diabetes, body 
mass index, vigorous physical activity, statin use, and metformin use. 
c Per 100,000 person-years. 
d Additionally adjusted for waist circumference, hypertension, and hypercholesterolemia. 
e Additionally adjusted for waist circumference, type 2 diabetes, and hypercholesterolemia. 
f  Additionally adjusted for waist circumference, type 2 diabetes, and hypertension. 
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6.2 Appendix 2:  Reproductive Factors and Endometrial Cancer Risk in U.S. 
Black Women  
 
6.2.1 Definitions of histologic subtypes of endometrial cancer by 
International Classification of Diseases for Oncology codes 
 Type I, Type II and Type III tumors were classified according to ICD-O 
codes as shown in Table 16. 
 
6.2.2  Associations of histologic subtypes of endometrial cancer with 
reproductive factors 
 Few differences between histologic subtypes were observed in their 
associations with reproductive factors (Table 17). Apparent differences in 
associations between the number- and timing of birth variables appears to be 
due to collinearity. 
 
6.2.3 Associations of reproductive factors with endometrial cancer, 
restricted to confirmed cases 
Associations tended to change only slightly when we analyzed confirmed 
cases, censoring all other incident cases (Tables 18, 19, 20). Some were 
attenuated and some strengthened. The associations of endometrial cancer with 
all age at last birth categories were above one, and with all years since last birth 
 114 
were below one, contrary to expectations. This is likely due to a combination of 
reduced precision and collinearity among the parity-related variables. 
 115 
Table 16. Histologic Subtypes of Uterine Cancer, Black Women’s Health Study, 1995–2013 
Uterine cancer subtype and ICD-O code N (%) 
Type 1  
8010 [carcinoma, NOS] 
8020 [carcinoma, undifferentiated type, NOS] 
8140 [adenocarcinoma] 
8210 [adenocarcinoma in adenomatous polyp] 
8255 [adenocarcinoma with mixed subtypes] 
8260 [papillar adenocarcinoma] 
8262 [villous adenocarcinoma] 
8263 [adenocarcinoma in tubulovillous adenoma] 
8380 [endometrioid] 
8382 [endometrioid adenocarcinoma, secretory variant] 
8383 [endometrioid adenocarcinoma, ciliated cell variant] 
8440 [cystadenocarcinoma] 
8480 [mucinous adenocarcinoma] 
8481 [mucin-producing adenocarcinoma]  
8570 [adenocarcinoma with squamous metaplasia]) 
131 (43.6) 
  
Type II 
8041 [small cell carcinoma] 
8050 [papillary carcinoma] 
8070 [squamous cell carcinoma, NOS] 
8071 [squamous cell carcinoma, keratinizing] 
8072 [squamous cell carcinoma, large cell, non-keratinizing] 
8310 [clear cell adenocarcinoma, NOS] 
8323 [mixed cell carcinoma] 
8441 [serous cystadenocarcinoma] 
8460 [papillary serous cystadenocarcinoma] 
8461 [serous surface papillary carcinoma] 
8560 [adenosquamous carcinoma]) 
30 (10.0) 
  
Type III 
8950 [mullerian mixed tumor] 
8951 [medsodermal mixed tumor] 
8980 [carcinosarcoma] 
21 (7.0) 
  
Unknown type 118 (39.3) 
Abbreviation: NOS, not otherwise specified. 
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Table 17. Incidence Rate Ratios for Subtypes of Endometrial Cancer According to Reproductive Factors 
  Type I  Type II/III 
 Cases Ratea IRRb 95% CI  Cases Ratea IRRb 95% CI 
Parity          
     Nulliparous 41 19.3 1.00 Referent  10 4.7 1.00 Referent 
     Parous 89 18.8 0.48 0.31, 0.75  41 8.7 0.65 0.29, 1.45 
          
Age at first birth, yearsd,e          
     <20 29 22.8 1.00 Referent  15 11.8 1.00 Referent 
     20–24 39 26.7 1.03 0.62, 1.72  12 8.2 0.76 0.34, 1.71 
     25–29 17 16.0 0.74 0.39, 1.42  12 11.3 1.94 0.81, 4.63 
     ≥30 4 4.6 0.18 0.06, 0.53  2 2.3 0.61 0.12, 2.98 
     Ptrend    0.001     0.66 
          
Age at last birth, yearsd          
    <25 29 23.0 1.00 Referent  11 8.7 1.00 Referent 
     25–29 30 22.4 2.12 1.04, 4.31  15 11.2 0.84 0.34, 2.11 
     30–34 17 13.6 2.11 0.87, 5.12  9 7.2 0.60 0.19, 1.88 
     ≥35 10 12.9 2.00 0.74, 5.46  5 6.5 0.48 0.13, 1.82 
     Ptrend    0.18     0.30 
          
Years since last birthd,e          
     <20 14 5.1 1.00 Referent  1 0.4 1.00 Referent 
     20–29 25 24.9 0.56 0.24, 1.29  10 10.0 2.67 0.31, 23.10 
     30–39 32 55.3 0.34 0.12, 0.93  15 25.9 3.36 0.32, 34.74 
     ≥40 15 67.8 0.19 0.05, 0.74  14 63.2 7.81 0.58, 104.79 
     Ptrend    0.008     0.27 
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Table 17. continued 
 Type I  Type II/III 
 Cases Ratea IRRb 95% CI  Cases Ratea IRRb 95% CI 
Breastfeedingd,e          
     No 53 20.9 1.00 Referent  24 9.5 1.00 Referent 
     Yes 36 16.4 1.25 0.80, 1.97  17 7.8 1.27 0.66, 2.46 
          <12 months 28 17.3 1.28 0.79, 2.07  8 5.0 0.88 0.38, 2.03 
          ≥12 months 8 15.2 1.16 0.52, 2.57  8 15.2 2.58 1.05, 6.35 
          
Lifetime number of  
   menstrual cycles 
         
     <300 10 2.9 1.00 Referent  2 0.6 1.00 Referent 
     300–399 35 19.0 2.36 1.11, 5.02  8 4.3 1.41 0.30, 6.75 
     400–499 54 41.4 2.78 1.27, 6.11  26 19.9 2.35 0.54, 10.13 
     ≥500 31 108.7 3.82 1.59, 9.14  15 52.5 2.37 0.50, 11.20 
     Ptrend    0.003     0.14 
          
Age at natural  
   menopause 
         
     <45 7 30.5 1.00 Referent  1 4.4 1.00 Referent 
     45–49 16 34.7 1.00 0.39, 2.59  10 21.7 4.34 0.54, 34.79 
     50–54 34 53.1 1.18 0.48, 2.86  13 20.3 2.90 0.37, 23.04 
     ≥55 14 73.1 1.20 0.44, 3.26  11 57.4 5.82 0.73, 46.77 
     Ptrend    0.61     0.11 
          
History of infertility          
     No 110 17.6 1.00 Referent  42 6.7 1.00 Referent 
     Yes 21 33.1 1.10 0.67, 1.79  9 14.2 1.51 0.70, 3.25 
          
Ever diagnosis of PCOS          
     No 130 19.1 1.00 Referent  51 7.5 1.00 Referent 
     Yes 1 14.3 0.98 0.14, 7.06  0 0.0 0.00 - 
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Table 17. continued 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio; PCOS, polycystic ovary syndrome. 
a Per 100,000 person-years. 
b Stratified jointly by age and study period. 
c Stratified by age and study period and adjusted for education, marital status, age at menarche, number of births, menopausal status, 
oral contraceptive use, estrogen-only female menopausal hormone use, estrogen plus progestin female menopausal hormone use, 
smoking status, body mass index, and vigorous physical activity. 
d Restricted to parous women. 
e Additionally adjusted for age at first birth. 
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Table 18. Incidence Rate Ratios for Endometrial Cancer According to Reproductive Factors, Confirmed 
Cases Only 
     
Age Adjusteda  
Multivariable 
Adjustedb 
Exposure Cases 
Person-
Years 
Ratec 
 
IRR 95% CI 
 
IRR 95% CI 
Age at menarche, years          
     <11 37 76,961 48.1  1.96 1.35, 2.87  1.58 1.08, 2.32 
     11 39 114,103 34.2  1.31 0.91, 1.90  1.18 0.81, 1.71 
     12–13 100 363,585 27.5  1.00 Referent  1.00 Referent 
     ≥14 37 131,845 28.1  0.88 0.61, 1.29  0.93 0.64, 1.36 
     Ptrend      0.002   0.05 
          
Parity          
     Nulliparous 54 216,448 25.4  1.00 Referent  1.00 Referent 
     Parous 158 473,214 33.4  0.55 0.40, 0.75  0.62 0.43, 0.89 
          
Number of birthsd,e          
     1 48 175,201 27.4  1.00 Referent  1.00 Referent 
     2 49 166,865 29.4  0.76 0.51, 1.13  0.70 0.46, 1.05 
     3 29 80,622 36.0  0.74 0.47, 1.19  0.63 0.39, 1.04 
     ≥4 32 50,526 63.3  0.84 0.53, 1.35  0.60 0.36, 1.01 
     Ptrend      0.43   0.05 
          
Age at first birth, yearsd          
     <20 53 127,657 41.5  1.00 Referent  1.00 Referent 
     20–24 61 146,045 41.8  0.99 0.69, 1.44  0.99 0.67, 1.46 
     25–29 37 106,158 34.9  1.10 0.72, 1.67  1.09 0.68, 1.74 
     ≥30 7 87,847 8.0  0.31 0.14, 0.67  0.27 0.12, 0.63 
     Ptrend      0.02   0.02 
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Table 18. continued          
     
Age Adjusteda  
Multivariable 
Adjustedb 
Exposure Cases 
Person-
Years 
Ratec 
 
IRR 95% CI 
 
IRR 95% CI 
Age at last birth, yearsd,e          
    <25 46 126,165 36.5  1.00 Referent  1.00 Referent 
     25–29 57 134,056 42.5  1.13 0.76, 1.66  1.41 0.87, 2.29 
     30–34 30 125,125 24.0  0.67 0.42, 1.06  1.12 0.60, 2.07 
     ≥35 21 77,446 27.1  0.64 0.38, 1.08  1.19 0.60, 2.37 
     Ptrend      0.02   0.75 
          
Years since last birthd,e          
     <20 17 275,035 6.2  1.00 Referent  1.00 Referent 
     20–29 42 100,511 41.8  1.39 0.69, 2.78  0.90 0.44, 1.83 
     30–39 64 57,992 110.4  1.73 0.83, 3.62  0.82 0.36, 1.88 
     ≥40 31 22,169 139.8  1.68 0.71, 3.97  0.61 0.22, 1.72 
     Ptrend      0.23   0.19 
          
Breastfeedingd,e          
     No 98 253,755 38.6  1.00 Referent  1.00 Referent 
     Yes 60 219,458 27.3  0.89 0.65, 1.24  1.05 0.74, 1.47 
          <12 months 41 161,533 25.4  0.86 0.60, 1.24  0.98 0.67, 1.43 
          ≥12 months 18 52,770 34.1  0.97 0.59, 1.61  1.21 0.71, 2.09 
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Table 18. continued 
     
Age Adjusteda  
Multivariable 
Adjustedb 
Exposure Cases 
Person-
Years 
Ratec 
 
IRR 95% CI 
 
IRR 95% CI 
Lifetime number of  
   menstrual cycles 
   
      
     <300 16 341,490 4.7  1.00 Referent  1.00 Referent 
     300–399 51 184,580 27.6  2.36 1.27, 4.38  1.97 1.08, 3.62 
     400–499 92 130,673 70.4  3.05 1.63, 5.74  2.38 1.28, 4.41 
     ≥500 53 28,580 185.4  5.38 2.77, 10.45  2.92 1.48, 5.77 
     Ptrend      <0.0001   0.002 
          
Age at natural  
   menopause, years 
   
 
  
 
  
     <45 10 22,974 43.5  1.00 Referent  1.00 Referent 
     45–49 33 46,181 71.5  1.44 0.69, 3.01  1.47 0.70, 3.10 
     50–54 56 64,073 87.4  1.33 0.66, 2.71  1.34 0.65, 2.75 
     ≥55 26 19,164 135.7  1.73 0.80, 3.73  1.52 0.70, 3.34 
     Ptrend      0.23   0.42 
          
History of infertility          
     No 180 626,269 28.7  1.00 Referent  1.00 Referent 
     Yes 33 63,393 52.1  1.11 0.76, 1.61  1.14 0.77, 1.69 
          
Ever diagnosis of PCOS          
     No 211 682,668 30.9  1.00 Referent  1.00 Referent 
     Yes 2 6,994 28.6  1.45 0.36, 5.84  1.20 0.30, 4.89 
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Table 18. continued 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio; PCOS, polycystic ovary syndrome. 
a Stratified jointly by age and study period. 
b Stratified by age and study period and adjusted for education, marital status, age at menarche, number of 
births, menopausal status, oral contraceptive use, estrogen-only female menopausal hormone use, 
estrogen plus progestin female menopausal hormone use, smoking status, BMI, and vigorous physical 
activity. 
c Crude incidence rate per 100,000 person-years. 
d Restricted to parous women. 
e Additionally adjusted for age at first birth. 
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Table 19. Incidence Rate Ratios for Endometrial Cancer According to Reproductive Factors, Stratified by Menopausal Status, Confirmed 
Cases Only 
 Premenopausal  Postmenopausal  
Exposure Cases Ratea IRRb 95% CI  Cases Ratea IRRb 95% CI Pinteraction 
Age at menarche,  
   years 
          
    <11 9 15.5 1.85 0.80, 4.25  23 140.5 1.42 0.88, 2.28  
     11 10 11.8 1.71 0.77, 3.80  26 102.0 1.09 0.70, 1.71  
     12–13 18 6.8 1.00 Referent  75 87.6 1.00 Referent  
     ≥14 15 16.4 2.68 1.32, 5.43  22 61.3 0.68 0.42, 1.10 0.16 
     Ptrend    0.42     0.03  
           
Age at first birth, yearsc           
     <20 9 11.4 1.00 Referent  40 92.3 1.00 Referent  
     20–24 14 15.2 0.90 0.36, 2.27  43 88.7 0.95 0.60, 1.50  
     ≥25 6 4.2 0.31 0.10, 2.43  36 83.0 1.04 0.61, 1.78 0.10 
     Ptrend    0.006     0.37  
           
Age at last birth,  
   yearsc,d 
          
    <25 11 13.1 1.00 Referent  30 80.7 1.00 Referent  
     25–29 8 8.8 1.52 0.43, 5.45  47 134.6 1.53 0.88, 2.65  
     30–34 5 5.7 1.24 0.25, 6.13  22 64.9 0.99 0.49, 2.03  
     ≥35 4 7.9 2.44 0.43, 13.77  17 70.6 1.09 0.50, 2.38 0.29 
     Ptrend    0.52     0.97  
Abbreviations: CI, confidence interval; IRR, incidence rate ratio. 
a Per 100,000 person-years. 
b Stratified by age and study period and adjusted for education, marital status, age at menarche, number of births, oral contraceptive 
use, estrogen-only female menopausal hormone use, estrogen plus progestin female menopausal hormone use, smoking status, BMI, 
and vigorous physical activity. 
c Restricted to parous women. 
d Additionally adjusted for age at first birth. 
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Table 20. Incidence Rate Ratios for Endometrial Cancer According to Reproductive Factors, Stratified by Obesity, Confirmed Cases Only 
 BMI < 30 kg/m2  BMI ≥ 30 kg/m2 
Exposure Cases Ratea IRRb 95% CI  Cases Ratea IRRb 95% CI Pinteraction 
Age at menarche, years           
     <11 7 19.3 1.11 0.49, 2.50  30 75.1 1.82 1.16, 2.85  
     11 8 12.6 0.81 0.38, 1.73  30 60.5 1.40 0.90, 2.19  
     12–13 40 17.1 1.00 Referent  58 45.8 1.00 Referent  
     ≥14 17 18.5 0.97 0.55, 1.73  20 51.8 0.97 0.58, 1.63 0.48 
     Ptrend    0.88     0.02  
           
Age at first birth, yearsc           
     <20 15 21.0 1.00 Referent  38 69.4 1.00 Referent  
     20–24 20 22.8 1.02 0.50, 2.07  40 70.6 1.01 0.63, 1.62  
     ≥25 17 13.5 0.76 0.33, 1.74  25 37.7 0.76 0.43, 1.36 0.92 
     Ptrend    0.14     0.05  
           
Breastfeedingc,d           
     No 38 25.5 1.00 Referent  57 56.0 1.00 Referent  
     Yes 14 10.0 0.50 0.26, 0.98  46 59.1 1.50 0.99, 2.28  
          <12 months 11 10.7 0.60 0.30, 1.23  30 52.4 1.27 0.80, 2.02  
          ≥12 months 3 8.9 0.38 0.11, 1.33  15 81.0 2.02 1.08, 3.78 0.02 
Abbreviations: BMI, body mass index; CI, confidence interval; IRR, incidence rate ratio. 
a Per 100,000 person-years. 
b Stratified by age and study period and adjusted for education, marital status, age at menarche, number of births, menopausal status, 
oral contraceptive use, estrogen-only female menopausal hormone use, estrogen plus progestin female menopausal hormone use, 
smoking status, body mass index (continuous), and vigorous physical activity. 
c Restricted to parous women. 
d Additionally adjusted for age at first birth. 
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6.3 Appendix 3: Exogenous Hormone Use and Endometrial Cancer in U.S. 
Black Women 
 
6.3.1 Analysis of pattern of progestin use at baseline 
 Pattern of progestin use in estrogen plus progestin FMH was only 
available at baseline (Table 21). We therefore analyzed this variable as time 
invariant, using age as the underlying time scale. We had too few exposed cases 
in all categories to draw definitive conclusions about the associations of 
endometrial cancer risk with different patterns of progestin use. However, our 
results are consistent with an increased risk in sequential formulations of 
estrogen plus progestin FMH, but decreased risk in continuous formulations. 
 
6.3.2 Analysis of associations of exogenous hormone use with histologic 
subtypes of endometrial cancer 
 We repeated our analyses by histologic subtype (type I, type II/III), 
censoring women at diagnosis of other subtypes or unknown subtype (Table 22). 
We had few cases of types II and III, and our estimates were imprecise. We did 
not find strong evidence of differences in the associations of different subtypes 
with exogenous hormone use, although we had small numbers of cases. 
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6.3.3 Associations of exogenous hormone use with endometrial cancer, 
restricted to confirmed cases 
Associations tended to be slightly attenuated when we analyzed confirmed 
cases, censoring those that were not validated (Table 23). 
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Table 21. Association of Endometrial Cancer With Pattern of Progestin Use in Estrogen 
Plus Progestin FMH, 1995 
Variable Cases N 
Person-
Years 
Ratea IRRb 95% CI 
Pattern of progestin use       
     Never used FMH 177 13,158 186,113 95.1 1.00 Referent 
     <2 weeks/month 11 512 7,836 140.4 1.42 0.76, 2.65 
     2–3 weeks/month 0 345 5,080 0.0 0.00  
     Continuous 8 600 9,442 84.7 0.83 0.40, 1.73 
     Other 1 98 1,390 71.9 0.67 0.09, 4.81 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio; FMH female 
menopausal hormones. 
a Crude incidence rate per 100,000 person-years. 
b Stratified by age and study period and adjusted for age at menarche, parity, 
menopausal status, oral contraceptive use, estrogen-only female menopausal 
hormone use, smoking status, body mass index, and vigorous physical activity. 
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Table 22. Associations of Endometrial Cancer Subtypes With Exogenous Hormone Use, 1995–2013 
 Type I  Type II/III 
Exposure Cases Ratea IRRb 95% CI  Cases Ratea IRRb 95% CI 
Oral contraceptive  
   usec,d 
         
     Never 24 30.2 1.00 Referent  13 16.3 1.00 Referent 
     Ever 107 17.5 1.00 0.62, 1.61  38 6.2 0.76 0.38, 1.53 
          Former 102 20.8 1.03 0.64, 1.66  33 6.8 0.73 0.36, 1.49 
               1–9 yearse 16 9.2 0.78 0.39, 1.57  4 2.3 0.72 0.21, 2.45 
               10–19 years 14 10.4 0.86 0.42, 1.75  2 1.5 0.44 0.09, 2.09 
               20–29 years  31 29.5 1.24 0.70, 2.19  7 6.7 0.63 0.23, 1.73 
               ≥30 years 37 59.6 1.02 0.59, 1.75  19 30.6 0.80 0.38, 1.70 
          Current 5 4.2 0.48 0.17, 1.38  5 4.2 1.57 0.43, 5.80 
          
     Duration, years          
          1–4 73 22.5 1.14 0.70, 1.87  24 7.4 0.77 0.37, 1.60 
          5–9 20 14.0 0.93 0.50, 1.74  4 2.8 0.44 0.14, 1.42 
          ≥10 8 6.5 0.38 0.16, 0.86  8 6.5 0.96 0.37, 2.50 
          
     Recency, years x    
       duration, yearsc 
         
          <10, <5 8 6.8 0.58 0.25, 1.37  4 3.4 0.87 0.25, 3.03 
          <10, ≥5 11 6.5 0.61 0.28, 1.35  4 2.4 0.92 0.26, 3.30 
          10–19, <5 11 14.4 1.37 0.63, 2.97  1 1.3 0.51 0.06, 4.02 
          10–19, ≥5 3 5.2 0.35 0.10, 1.21  1 1.7 0.40 0.05, 3.27 
          ≥20, <5 54 41.6 1.22 0.73, 2.02  19 14.6 0.78 0.37, 1.66 
          ≥20, ≥5 14 37.5 0.76 0.38, 1.51  7 18.7 0.68 0.26, 1.78 
          
Estrogen–only FMH  
   used,f,g 
         
     Neverh 76 27.4 1.00 Referent  29 10.5 1.00 Referent 
     Ever 6 48.5 1.01 0.43, 2.35  2 11.0 0.74 0.17, 3.17 
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Table 22. continued 
 Type I  Type II/III 
Exposure Cases Ratea IRRb 95% CI  Cases Ratea IRRb 95% CI 
Estrogen plus   
   progestin FMH  
   usec,d,e 
         
     Neverh 76 27.4 1.00 Referent  29 10.5 1.00 Referent 
     Ever 12 41.6 0.75 0.40, 1.41  4 13.9 0.56 0.19, 1.66 
          
Progestin-only  
   FMH usec,d,f,g 
         
     Neverh 100 29.0 1.00 Referent  39 11.3 1.00 Referent 
     Ever 3 40.7 1.01 0.31, 3.26  1 13.6 1.29 0.17, 9.78 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio; FMH female menopausal hormones. 
a Crude rate per 100,000 person-years. 
b Stratified by age and study period and adjusted for age at menarche, parity, menopausal status, smoking status, body mass index, 
and vigorous physical activity. 
c Additionally adjusted for estrogen-only FMH use 
d Additionally adjusted for estrogen plus progestin FMH use 
e Years since last use  
f Additionally adjusted for oral contraceptive use. 
g Analysis restricted to women ≥40 years of age, not taking oral contraceptives, with known menopause status, and not reporting use of 
multiple FMH types 
h Never used any type of FMH 
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Table 23. Associations of Endometrial Cancer With Exogenous Hormone Use, 
Confirmed Cases Only, 1995–2013 
Exposure Cases Ratea IRRb 95% CI 
Oral contraceptive usec,d     
     Never 45 56.5 1.00 Referent 
     Ever 168 27.5 0.87 0.43, 4.52 
          Former 156 31.9 0.88 0.61, 1.26 
               1–9 years 111 34.1 0.95 0.65, 1.38 
               10–19 years 30 21.0 0.81 0.49, 1.32 
               20–29 years 18 14.7 0.51 0.29, 0.90 
               ≥30 years 68 109.3 0.93 0.62, 1.39 
          Current 12 10.0 0.71 0.34, 1.46 
     
     Duration, years     
          1–4 111 34.1 0.95 0.65, 1.38 
          5–9 30 21.0 0.81 0.49, 1.32 
          ≥10 18 14.7 0.51 0.29, 0.90 
     
     Recency, years x  
        duration, years 
    
          <10, <5 13 11.0 0.51 0.27, 0.97 
          <10, ≥5 16 9.5 0.52 0.28, 0.96 
          10–19, <5 13 17.0 0.97 0.51, 1.87 
          10–19, ≥5 5 8.6 0.37 0.14, 0.95 
          ≥20, <5 85 65.5 0.99 0.69, 1.44 
          ≥20, ≥5 27 72.2 0.77 0.47, 1.25 
     
Estrogen-only FMH used,e,f     
     Neverg 120 43.2 1.00 Referent 
     Ever 19 88.7 1.05 0.56, 1.96 
          Former 5 54.9 0.56 0.23, 1.40 
          Current 6 182.1 3.55 1.49, 8.46 
     
Estrogen plus progestin   
   FMH usec,e,f 
    
     Neverg 120 43.2 1.00 Referent 
     Ever 21 72.8 0.77 0.48, 1.26 
          Former 13 72.4 0.60 0.33, 1.09 
          Current 8 73.6 1.47 0.68, 3.20 
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Table 23. continued 
Exposure Cases Rate1 IRR2 95% CI 
Progestin only FMH usec,d,e,f     
     Neverg 120 43.2 1.00 Referent 
     Ever 5 67.7 1.18 0.48, 2.93 
Abbreviations: CI, confidence interval; IRR, incidence rate ratio; FMH female 
menopausal hormones. 
a Crude rate per 100,000 person-years. 
b Stratified by age and study period and adjusted for age at menarche, parity, 
menopausal status, smoking status, body mass index, and vigorous physical 
activity. 
c Additionally adjusted for estrogen-only FMH use. 
d Additionally adjusted for estrogen plus progestin FMH use. 
e Additionally adjusted for oral contraceptive use. 
f Restricted to women ≥40 years of age, not taking oral contraceptives, of 
known menopausal status, and not reporting use of multiple types of FMH. 
g Never used any FMH type. 
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